U.S. Stem Cell (USRM) 10-Q 5 Nov 15 2015 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Sep. 30, 2015	Nov. 05, 2015
Document and Entity Information [Abstract]
Entity Registrant Name	U.S. STEM CELL, INC.
Document Type	10-Q
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		1,283,757
Amendment Flag	false
Entity Central Index Key	1,388,319
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Smaller Reporting Company
Entity Well-known Seasoned Issuer	Yes
Document Period End Date	Sep. 30, 2015
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	Q3

CONDENSED BALANCE SHEETS

CONDENSED BALANCE SHEETS - USD ($)	Sep. 30, 2015	Dec. 31, 2014
Current assets:
Cash and cash equivalents	$ 65,658	$ 36,674
Accounts receivable, net	93,770	95,409
Prepaid and other	9,155	9,255
Total current assets	168,583	141,338
Property and equipment, net	9,633	12,686
Other assets
Investments	74,530	40,597
Deposits	10,160	10,160
Total assets	262,906	204,781
Current liabilities:
Accounts payable	2,025,825	1,991,979
Accrued expenses	656,141	2,373,615
Advances, related party	155,363	148,759
Deferred revenue	32,170	0
Deposits	478,286	478,286
Promissory note, short term portion, net of debt discount of $80,754 and $-0- respectively	69,246	1,500,000
Notes payable, related party	2,242,262	2,333,059
Notes payable, net of debt discount	1,635,500	1,531,812
Derivative liabilities	399,328	741,271
Total current liabilities	7,694,121	11,098,781
Long term debt:
Promissory note, long term portion, net of debt discount of $259,720	1,288,043	0
Total liabilities	8,982,164	11,098,781
Commitments and contingencies	0	0
Stockholders' deficit:
Preferred stock, par value $0.001; 20,000,000 shares authorized, 20,000,000 issued and outstanding	20,000	20,000
Common stock, par value $0.001; 2,000,000,000 shares authorized, 977,806 and 581,433 shares issued and 939,954 and 581,433 outstanding as of September 30, 2015 and December 31, 2014, respectively	978	581
Additional paid in capital	112,134,904	109,519,913
Treasury stock, 37,852 shares	(157,664)	0
Accumulated deficit	(120,717,476)	(120,434,494)
Total stockholders' deficit	(8,719,258)	(10,894,000)
Total liabilities and stockholders' deficit	$ 262,906	$ 204,781

CONDENSED BALANCE SHEETS (Paren

CONDENSED BALANCE SHEETS (Parentheticals) - USD ($)	Sep. 30, 2015	Dec. 31, 2014
Promissory note, debt discount (in Dollars)	$ 180,032	$ 339,160
Preferred stock, par value (in Dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	20,000,000	20,000,000
Preferred stock, shares issued	20,000,000	20,000,000
Preferred stock, shares outstanding	20,000,000	20,000,000
Common stock, par value (in Dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	2,000,000,000	2,000,000,000
Common stock, shares issued	977,806	581,433
Common stock, shares outstanding	939,954	581,433
Treasury stock, shares	37,852
Notes Payable, Other Payables [Member]
Promissory note, debt discount (in Dollars)	$ 259,720
Notes Payable, Other Payables [Member]
Promissory note, debt discount (in Dollars)	$ 80,754	$ 0

CONDENSED STATEMENTS OF OPERATI

CONDENSED STATEMENTS OF OPERATIONS (unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Revenue:
Products	$ 321,129	$ 281,752	$ 949,251	$ 869,012
Services	236,483	297,784	663,225	694,852
Total revenue	557,612	579,536	1,612,476	1,563,864
Cost and operating expenses:
Cost of sales	243,940	455,603	868,742	782,487
Research and development	12,764	8,581	39,696	33,916
Marketing, general and administrative	563,676	1,580,325	2,252,057	3,289,419
Depreciation and amortization	1,328	1,759	3,947	3,745
Total operating expenses	821,708	2,046,268	3,164,442	4,109,567
Net loss from operations	(264,096)	(1,466,732)	(1,551,966)	(2,545,703)
Other income (expenses):
Gain on settlement of debt	58,873	85,229	2,097,483	2,272,283
Gain on change of fair value of derivative liability	374,684	239,296	260,953	61,339
Income from equity investment	11,625	0	23,934	0
Other income	10,131	0	13,282	0
Interest expense	(312,576)	(331,026)	(1,126,668)	(1,035,118)
Total other income (expenses)	142,737	(6,501)	1,268,984	1,298,504
Net loss before income taxes	(121,359)	(1,473,233)	(282,982)	(1,247,199)
Income taxes (benefit)	0	0	0	0
NET LOSS	$ (121,359)	$ (1,473,233)	$ (282,982)	$ (1,247,199)
Net loss per common share, basic and diluted (in Dollars per share)	$ (0.15)	$ (2.84)	$ (0.38)	$ (2.68)
Weighted average number of common shares outstanding, basic and diluted (in Shares)	835,113	519,135	736,269	464,608

CONDENSED STATEMENT OF STOCKHOL

CONDENSED STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT) (unaudited) - 9 months ended Sep. 30, 2015 - USD ($)	Common Stock Issued in Settlement of Accounts Payable, Accrued Expenses and Accrued Interest [Member]Common Stock [Member]	Common Stock Issued in Settlement of Accounts Payable, Accrued Expenses and Accrued Interest [Member]Additional Paid-in Capital [Member]	Common Stock Issued in Settlement of Accounts Payable, Accrued Expenses and Accrued Interest [Member]	Common Stock Issued in Settlement of Guarantor Fees [Member]Common Stock [Member]	Common Stock Issued in Settlement of Guarantor Fees [Member]Additional Paid-in Capital [Member]	Common Stock Issued in Settlement of Guarantor Fees [Member]	Common Stock Issued in Settlement of Other Debt [Member]Common Stock [Member]	Common Stock Issued in Settlement of Other Debt [Member]Additional Paid-in Capital [Member]	Common Stock Issued in Settlement of Other Debt [Member]	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Treasury Stock [Member]	Retained Earnings [Member]	Total
Balance at Dec. 31, 2014										$ 20,000	$ 581	$ 109,519,913	$ 0	$ (120,434,494)	$ (10,894,000)
Balance (in Shares) at Dec. 31, 2014										20,000,000	581,433
Common stock issued settlement of debt	$ 22	$ 165,390	$ 165,412	$ 24	$ 170,077	$ 170,101	$ 248	$ 1,295,340	$ 1,295,588
Common stock issued settlement of debt (in Shares)	22,182			24,353			247,524
Proceeds from issuance of common stock											$ 96	582,712			582,808
Proceeds from issuance of common stock (in Shares)											95,664
Common stock issued in settlement of litigation											$ 7	59,843			$ 59,850
Common stock issued in settlement of litigation (in Shares)											6,650				6,650
Purchase of 37,852 shares of Company's common stock at average cost of $4.17 per share													(157,664)		$ (157,664)
Stock based compensation												341,629			341,629
Net loss														(282,982)	(282,982)
Balance at Sep. 30, 2015										$ 20,000	$ 978	$ 112,134,904	$ (157,664)	$ (120,717,476)	$ (8,719,258)
Balance (in Shares) at Sep. 30, 2015										20,000,000	977,806

CONDENSED STATEMENT OF STOCKHO6

CONDENSED STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT) (unaudited) (Parentheticals) - Common Stock [Member]	9 Months Ended
	Sep. 30, 2015$ / sharesshares
Purchase of Company's Common Stock, Shares | shares	37,852
Purchase of Company's Common Stock, Average Cost Per Share	$ 4.17

CONDENSED STATEMENTS OF CASH FL

CONDENSED STATEMENTS OF CASH FLOWS (unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (282,982)	$ (1,247,199)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	3,947	3,745
Bad debt expense	0	28,732
Discount on convertible debt	612,811	343,592
Change in fair value of derivative liability	(260,953)	(61,339)
Gain on settlement of debt	(2,097,483)	(2,272,283)
Common stock issued in settlement of litigation	59,850	0
Non cash payment of interest	227,396	385,501
Warrants issued in connection with joint venture agreement	0	136,837
Related party notes payable issued for services rendered	0	800,000
Income on equity investments	(23,934)	0
Stock based compensation	341,629	446,366
(Increase) decrease in:
Receivables	1,639	(162,682)
Prepaid and other current assets	100	(23,624)
Increase (decrease) in:
Accounts payable	324,026	628,684
Accrued expenses	272,322	246,486
Deferred revenue	32,170	0
Net cash used in operating activities	(789,462)	(747,184)
CASH FLOWS FROM INVESTING ACTIVITIES:
Payments for investments	(10,000)	0
Purchase of treasury stock	(157,664)	0
Acquisitions of property and equipment	(894)	(8,121)
Net cash used by investing activities	(168,558)	(8,121)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock, net	582,808	428,251
Proceeds from related party advances	6,604	26,759
Proceeds from exercise of stock options and warrants	0	136,000
Proceeds from notes payable	541,410	388,000
Repayments of notes payable	(143,818)	(223,340)
Net cash provided in financing activities	987,004	755,670
Net increase in cash and cash equivalents	28,984	365
Cash and cash equivalents, beginning of period	36,674	46,227
Cash and cash equivalents, end of period	65,658	46,592
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION
Interest paid	273,883	161,532
Income taxes paid	0	0
Non cash financing activities:
Promissory note issued in exchange for subordinated debt and accrued expenses	1,697,762	0
Common Stock Issued in Settlement of Notes Payable [Member]
Non cash financing activities:
Non-cash financing activities, stock issued	623,237	938,075
Common Stock Issued in Settlement of Accounts Payable [Member]
Non cash financing activities:
Non-cash financing activities, stock issued	165,412	857,445
Common Stock Issued in Settlement of Guarantor Fees [Member]
Non cash financing activities:
Non-cash financing activities, stock issued	170,101	0
Common Stock Issued in Settlement of Related Party Notes and Advances Payable [Member]
Non cash financing activities:
Non-cash financing activities, stock issued	$ 0	$ 862,880

NOTE 1 - SIGNIFICANT ACCOUNTING

NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES	9 Months Ended
	Sep. 30, 2015
Accounting Policies [Abstract]
Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]	NOTE 1 — SIGNIFICANT ACCOUNTING POLICIES A summary of the significant accounting policies applied in the presentation of the accompanying unaudited condensed financial statements follows: General The accompanying unaudited condensed financial statements of U.S. Stem Cell, Inc. (f.k.a. Bioheart, Inc.), (the “Company”), have been prepared in accordance with the rules and regulations (Regulation S-X) of the Securities and Exchange Commission (the “SEC”) and with the instructions to Form 10-Q. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. The results from operations for the three and nine month periods ended September 30, 2015 are not necessarily indicative of the results that may be expected for the year ended December 31, 2015. The unaudited condensed financial statements should be read in conjunction with the December 31, 2014 financial statements and notes thereto included in the Company’s Annual Report on Form 10-K. Basis and business presentation U.S. Stem Cell, Inc. (f.k.a. Bioheart, Inc.) (the “Company”) was incorporated under the laws of the State of Florida in August, 1999. The Company is in the cardiovascular sector of the cell technology industry delivering cell therapies and biologics that help address congestive heart failure, lower limb ischemia, chronic heart ischemia, acute myocardial infarctions and other issues. The business includes the development of proprietary cell therapy products as well as revenue generating physician and patient based regenerative medicine/cell therapy training services, cell collection and cell storage services, the sale of cell collection and treatment kits for humans and animals, and the operation of a cell therapy clinic. To date, the Company has not generated significant sales revenues in that they remain less than their total operating expenses, has incurred expenses, and has sustained losses. Consequently, its operations are subject to all the risks inherent in the establishment of a research and development business enterprise. On October 12, 2015, the Company amended its Articles of Incorporation to change its name to U.S. Stem Cell, Inc. and to implement a reverse stock split in the ratio of 1 share for every 1,000 shares of common stock. This amendment was approved and filed of record by the Florida Secretary of State on October 12, 2015, effective on October 19, 2015. FINRA has declared the Company’s 1-for-1,000 reverse stock split market effective as of November 4, 2015. In addition, the ticker symbol will be BHRTD for 20 business days from November 4 th . These financial statements have been retroactively restated to reflect the reverse stock split (see note 10). Revenue Recognition The Company recognizes revenue in accordance with Accounting Standards Codification subtopic 605-10, Revenue Recognition (“ASC 605-10”) which requires that four basic criteria must be met before revenue can be recognized: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred; (3) the selling price is fixed and determinable; and (4) collectability is reasonably assured. Determination of criteria (3) and (4) are based on management’s judgments regarding the fixed nature of the selling prices of the products delivered and the collectability of those amounts. Provisions for discounts and rebates to customers, estimated returns and allowances, and other adjustments are provided for in the same period the related sales are recorded. At the time of each transaction, management assesses whether the fee associated with the transaction is fixed or determinable and whether or not collection is reasonably assured. The assessment of whether the fee is fixed or determinable is based upon the payment terms of the transaction. Collectability is assessed based on a number of factors, including past transaction history with the client and the creditworthiness of the client. Revenues for test kits and equipment sold are not recorded until test kits are delivered. The Company has revenue sharing arrangements for the sale of goods whereby the Company is the primary obligor, sets pricing with the customers and bears all associated credit risks with the customers. Sales under revenue share arrangements are recorded as gross sales and any portion shared with third parties under such arrangements are classified as selling expense due to the nature of the marketing activities performed by the third party. Revenues from trainings are not recorded until the completion of the training. Any cash received as a deposit for trainings are recorded by the company as a liability. Patent treatments and laboratory services revenue are recognized when those services have been completed or satisfied. Revenues for bank sales are accounted for as Multiple-Element Arrangements under ASC 605-10 which incorporates Accounting Standards Codification subtopic 605-25, Multiple-Element Arrangements (“ASC 605-25”). ASC 605-25 addresses accounting for arrangements that may involve the delivery or performance of multiple products, services and/or rights to use assets. At September 30, 2015 and December 31, 2014, the Company had deferred revenues of $32,170 and $-0-, respectively. Accounts Receivable Trade receivables are carried at their estimated collectible amounts. Trade credit is generally extended on a short-term basis; thus trade receivables do not bear interest. Trade accounts receivable are periodically evaluated for collectability based on past credit history with customers and their current financial condition. Allowance for Doubtful Accounts Any changes to the allowance for doubtful accounts on accounts receivable are changed to operations in amounts sufficient to maintain the allowance for uncollectible accounts at a level management believes is adequate to cover any probable losses. Management determines the adequacy of the allowance based on historical write-off percentages and the current status of accounts receivable. Accounts receivable are charged off against the allowance when collectability is determined to be permanently impaired. As of September 30, 2015 and December 31, 2014, allowance for doubtful accounts was $-0-. Investments The Company has adopted Accounting Standards Codification subtopic 323-10, Investments-Equity Methods and Joint Ventures (“ASC 323-10) which requires the accounting for investments where the Company can exert significant influence, but not control of a joint venture or equity investment. The Company accounted for its 33 percent ownership of U.S. Stem Cell Clinic, LLC utilizing the equity method of accounting. Net Loss per Common Share, basic and diluted The Company has adopted Accounting Standards Codification subtopic 260-10, Earnings Per Share (“ASC 260-10”) specifying the computation, presentation and disclosure requirements of earnings per share information. Basic loss per share has been calculated based upon the weighted average number of common shares outstanding. Shares issuable upon conversion of convertible debt, stock options and warrants have been excluded as common stock equivalents in the diluted loss per share for the three and nine months ended September 30, 2015 and 2014 because their effect is anti-dilutive on the computation. Fully diluted shares outstanding were 1,206,554 and 659,543 for the three months ended September 30, 2015 and 2014, respectively and 1,107,710 and 605,016 for the nine months ended September 30, 2015 and 2014, respectively. Stock based compensation The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. For employees and directors, the fair value of the award is measured on the grant date and for non-employees, the fair value of the award is generally re-measured on vesting dates and interim financial reporting dates until the service period is complete. The fair value amount is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period. Stock-based compensation expense is recorded by the Company in the same expense classifications in the statements of operations, as if such amounts were paid in cash. As of September 30, 2015, there were outstanding stock options to purchase 73,804 shares of common stock, 44,468 shares of which were vested. Concentrations of Credit Risk The Company’s financial instruments that are exposed to a concentration of credit risk are cash and accounts receivable. Generally, the Company’s cash and cash equivalents in interest-bearing accounts does not exceed FDIC insurance limits. The financial stability of these institutions is periodically reviewed by senior management. As of September 30, 2015, five customers represented 15%, 5%, 7%, 15% and 14% respectively for an aggregate of 56% of the Company’s accounts receivable. As of December 31, 2014, two customers represented 38% and 17%, for an aggregate of 55%, of the Company’s accounts receivable. For the three months ended September 30, 2015, the Company’s revenues earned from the sale of products and services were $557,612, of which one customer represented 11% of the Company’s revenues. For the three months ended September 30, 2014, the Company’s revenues earned from the sale of products and services were $579,536, of which no customers represented 10% or more of the Company’s revenues. For the nine months ended September 30, 2015, the Company’s revenues earned from the sale of products and services were $1,612,476, of which no customers represented 10% or more of the Company’s revenues. For the nine months ended September 30, 2014, the Company’s revenues earned from the sale of products and services were $1,563,864, of which one customer represented 11% of the Company’s revenues. Research and Development The Company accounts for research and development costs in accordance with Accounting Standards Codification subtopic 730-10, Research and Development (“ASC 730-10”). Under ASC 730-10, all research and development costs must be charged to expense as incurred. Accordingly, internal research and development costs are expensed as incurred. Third-party research and development costs are expensed when the contracted work has been performed or as milestone results have been achieved as defined under the applicable agreement. Company-sponsored research and development costs related to both present and future products are expensed in the period incurred. The Company incurred research and development expenses of $12,764 and $39,696 for the three and nine months ended September 30, 2015, respectively; and $8,581 and $33,916 for the three and nine months ended September 30, 2014, respectively. Fair Value Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”) requires disclosure of the fair value of certain financial instruments. The carrying value of cash and cash equivalents, accounts payable and accrued liabilities, and short-term borrowings, as reflected in the balance sheets, approximate fair value because of the short-term maturity of these instruments. All other significant financial assets, financial liabilities and equity instruments of the Company are either recognized or disclosed in the financial statements together with other information relevant for making a reasonable assessment of future cash flows, interest rate risk and credit risk. Where practicable the fair values of financial assets and financial liabilities have been determined and disclosed; otherwise only available information pertinent to fair value has been disclosed. The Company follows Accounting Standards Codification subtopic 820-10, Fair Value Measurements and Disclosures (“ASC 820-10”) and Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”), which permits entities to choose to measure many financial instruments and certain other items at fair value. Derivative Instrument Liability The Company accounts for derivative instruments in accordance with ASC 815, which establishes accounting and reporting standards for derivative instruments and hedging activities, including certain derivative instruments embedded in other financial instruments or contracts and requires recognition of all derivatives on the balance sheet at fair value, regardless of hedging relationship designation. Accounting for changes in fair value of the derivative instruments depends on whether the derivatives qualify as hedge relationships and the types of relationships designated are based on the exposures hedged. At September 30, 2015 and December 31, 2014, the Company did not have any derivative instruments that were designated as hedges. At September 30, 2015 and December 31, 2014, the Company had outstanding convertible notes that contained embedded derivatives. These embedded derivatives include certain conversion features and reset provisions. (See Note 7 and Note 9) Reliance on Key Personnel and Consultants The Company has four full-time employees and one part-time employee. The Company is heavily dependent on the continued active participation of its two current executive officers, one employee and key consultants. The loss of any of the senior management or key consultants could significantly and negatively impact the business until adequate replacements can be identified and put in place. Reclassification Certain reclassifications have been made to prior periods’ data to conform with the current year’s presentation. These reclassifications had no effect on reported income or losses. Recent Accounting Pronouncements There were various updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on the Company’s financial position, results of operations or cash flows.

NOTE 2 - GOING CONCERN MATTERS

NOTE 2 - GOING CONCERN MATTERS	9 Months Ended
	Sep. 30, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Substantial Doubt about Going Concern [Text Block]	NOTE 2 — GOING CONCERN MATTERS The accompanying unaudited condensed financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As shown in the accompanying unaudited condensed financial statements, during nine months ended September 30, 2015, the Company incurred an operating loss of $1,551,966 and used $789,462 in cash for operating activities. As of September 30, 2015, the Company had a working capital deficit (current liabilities in excess of current assets) of approximately $7.5 million. These factors among others may indicate that the Company will be unable to continue as a going concern for a reasonable period of time. The Company’s existence is dependent upon management’s ability to develop profitable operations and to obtain additional funding sources. There can be no assurance that the Company’s financing efforts will result in profitable operations or the resolution of the Company’s liquidity problems. The accompanying statements do not include any adjustments that might result should the Company be unable to continue as a going concern.

NOTE 3 - INVESTMENTS

NOTE 3 - INVESTMENTS	9 Months Ended
	Sep. 30, 2015
Equity Method Investments and Joint Ventures [Abstract]
Equity Method Investments and Joint Ventures Disclosure [Text Block]	NOTE 3 — INVESTMENTS Investment is comprised of a 33% ownership of U.S. Stem Cell Clinic, LLC, accounted for using the equity method of accounting. The investments in 2014 and 2015 of cash and expenses paid on U.S. Stem Cell Clinic, LLC’s behalf were an aggregate of $59,714. The Company’s 33% income earned by U.S. Stem Cell Clinic, LLC of $11,625 and $23,934 for the three and nine months ended September 30, 2015, respectively, (inception to date income of $14,816) was recorded as other income/expense in the Company’s Statement of Operations in the appropriate periods and increased the carrying value of the investment to $74,530.

NOTE 4 - PROPERTY AND EQUIPMENT

NOTE 4 - PROPERTY AND EQUIPMENT	9 Months Ended
	Sep. 30, 2015
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment Disclosure [Text Block]	NOTE 4 — PROPERTY AND EQUIPMENT Property and equipment as of September 30, 2015 and December 31, 2014 summarized as follows: September 30, 2015 December 31, 2014 Laboratory and medical equipment $ 353,252 $ 352,358 Furniture, fixtures and equipment 125,634 125,634 Computer equipment 47,647 47,647 Leasehold improvements 362,046 362,046 888,579 887,685 Less accumulated depreciation and amortization (878,946 ) (874,999 ) $ 9,633 $ 12,686 Property and equipment are recorded on the basis of cost. For financial statement purposes, property, plant and equipment are depreciated using the straight-line method over their estimated useful lives. Expenditures for repair and maintenance which do not materially extend the useful lives of property and equipment are charged to operations. When property or equipment is sold or otherwise disposed of, the cost and related accumulated depreciation are removed from the respective accounts with the resulting gain or loss reflected in operations. Management periodically reviews the carrying value of its property and equipment for impairment in accordance with the guidance for impairment of long lived assets.

NOTE 5 - ACCRUED EXPENSES

NOTE 5 - ACCRUED EXPENSES	9 Months Ended
	Sep. 30, 2015
Payables and Accruals [Abstract]
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	NOTE 5 — ACCRUED EXPENSES Accrued expenses consisted of the following as of September 30, 2015 and December 31, 2014: September 30, 2015 December 31, 2014 Amounts payable to the Guarantors of the Company’s loan agreement with Bank of America and Seaside Bank, including fees and interest $ 40,205 $ 1,533,217 Interest payable on notes payable 451,937 685,575 Vendor accruals and other 141,582 120,836 Employee commissions, compensation, etc. 22,417 33,987 $ 656,141 $ 2,373,615 During the nine months ended September 30, 2014, the Company issued an aggregate of 45,232 shares of its common stock in settlement of outstanding accounts payable and accrued expenses. In connection with the issuance, the Company incurred $105,737 loss in settlement of debt. During the nine months ended September 30, 2015, the Company issued an aggregate of 20,819 shares of its common stock in settlement of outstanding accounts payable. In connection with the issuance, the Company incurred $86,763 gain in settlement of debt. During the nine months ended September 30, 2015, the Company incurred a gain of $50,638 in relief of accounts payable. During the nine months ended September 30, 2015, the Company issued an aggregate of 24,353 shares of its common stock in settlement of accumulative outstanding accounts payable due to Guarantors of the Company of $961,124. In connection with the issuance, the Company incurred a $791,024 gain in settlement of debt. During the nine months ended September 30, 2015, the Company settled an outstanding subordinated debt, related accrued interest and accounts payable due to the guarantor by issuing a five year, non-interest bearing note payable. (See Note 7). In connection with the note issuance, the Company settled $624,737 of outstanding guarantor fees.

NOTE 6 - STOCK PURCHASE AGREEME

NOTE 6 - STOCK PURCHASE AGREEMENT	9 Months Ended
	Sep. 30, 2015
Stock Purchase Agreement Disclosure [Abstract]
Stock Purchase Agreement Disclosure [Text Block]	NOTE 6 – STOCK PURCHASE AGREEMENT On October 23, 2014, the Company, entered into a common stock purchase agreement (the “Purchase Agreement”) with Magna Equities II, LLC, a New York limited liability company (the “Investor”). The Purchase Agreement provides that, upon the terms and subject to the conditions set forth therein, the Investor is committed to purchase up to $3,000,000 (the “Total Commitment”) worth of the Company’s common stock, $0.001 par value (the “Shares”), over the 24-month term of the Purchase Agreement. From time to time over the term of the Purchase Agreement, commencing on the trading day immediately following the date on which the initial registration statement was declared effective by the Securities and Exchange Commission (the “Commission”), the Company may provide the Investor with a draw down notice to purchase a specified dollar amount of Shares, with each draw down subject to certain limitations. The Company may not deliver any Draw Down Notice to the Investor if the Initial Purchase Price with respect to the Shares subject to such Draw Down Notice is less than $2.50 as of the date the applicable Draw Down Notice is received by the Investor (the “Draw Down Exercise Date”). The applicable Initial Purchase Price, the “Initial Purchase Price”, is defined as a price equal to 93% of the lowest of (i) the arithmetic average of the three lowest daily volume weighted average prices for the Company’s common stock (the “ VWAP In 2014, the Company paid to the Investor as a commitment fee for entering into the Purchase Agreement equal an aggregate of to 12,000 shares of the Company’s common stock. During the nine months ended September 30, 2015, the Company issued an aggregate of 87,812 shares of its common stock in exchange for $521,538 under the Purchase Agreement. (See Note 10)

NOTE 7 - NOTES PAYABLE

NOTE 7 - NOTES PAYABLE	9 Months Ended
	Sep. 30, 2015
Debt Disclosure [Abstract]
Debt Disclosure [Text Block]	NOTE 7 — NOTES PAYABLE Notes payable were comprised of the following as of September 30, 2015 and December 31, 2014: September 30, 2015 December 31, 2014 Seaside Bank note payable. $ 980,000 $ 980,000 Hunton & Williams notes payable 384,972 384,972 Asher notes payable 66,000 151,000 Daniel James Management notes payable 75,000 75,000 Fourth Man, LLC notes payable 75,000 75,000 Magna Group note payable 64,595 205,000 Power Up Lending Group notes payable 169,965 - Total notes payable 1,815,532 1,870,972 Less unamortized debt discount (180,032 ) (339,160 ) Total notes payable net of unamortized debt discount $ 1,635,500 $ 1,531,812 Seaside Bank On October 25, 2010, the Company entered into a Loan Agreement with Seaside National Bank and Trust for a $980,000 loan at 4.25% per annum interest that was used to refinance the Company’s loan with Bank of America. The obligation is guaranteed by certain shareholders of the Company. The Company renewed the loan with Seaside National Bank and Trust during the first quarter of 2014 to extend the maturity date to December 23, 2015. Hunton & Williams Notes At September 30, 2015 and December 31, 2014, the Company has two outstanding notes payable with interest at 8% per annum due at maturity. The two notes, $61,150 and $323,822, are payable in one balloon payment upon the date the Noteholder provides written demand, however the Company is not obligated to make payments until the Northstar (or successor) Loan is paid off. Asher Notes (During this period) During the nine months ended September 30, 2015, the Company entered into Securities Purchase Agreements with Asher Enterprises, Inc. (“Asher”) or affiliates, for the sale of 8% convertible notes in aggregate principal amount of $180,000 (the “Asher Notes”). The Company incurred legal fees in the amount of $15,000 which were deducted from the proceeds of the notes. The Asher Notes bear interest at the rate of 8% per annum. As of the nine months ended September 30, 2015, all interest and principal must be repaid nine months from the issuance date, with the last note being due February 6, 2016. The Asher Notes are convertible into shares of common stock, at Asher’s option, at a 45% discount to the average of the three lowest closing bid prices of the shares of common stock during the 10 trading day period prior to conversion. The Company has identified the embedded derivatives related to the Asher Notes. (see note 9) These embedded derivatives included certain conversion features and reset provision. The accounting treatment of derivative financial instruments requires that the Company record fair value of the derivatives as of the inception date of Asher Notes and to fair value as of each subsequent reporting date, which at September 30, 2015 was $72,522. At the inception of the Asher Notes, the Company determined the aggregate fair value of $211,575 of the embedded derivatives. During the nine months ended September 30, 2015, $151,000 of notes plus accrued interest that were outstanding at December 31, 2014, and $114,000 of notes plus accrued interest that were issued during 2015, were converted into shares of the Company’s common stock (see Note 10). The remaining aggregate Asher Notes unconverted principle balance as of September 30, 2015 was $66,000. Daniel James Management (During this period) During the nine months ended September 30, 2015, the Company entered into Securities Purchase Agreements with Daniel James Management (“Daniel”) for the sale of 9.5% convertible note in aggregate principal amount of $100,000 (the “Daniel Notes”). The Daniel Notes bear interest at the rate of 9.5% per annum. As of the nine months ended September 30, 2015, all interest and principal must be repaid one year from the issuance date, with the last note being due September 1, 2016. The Daniel Notes are convertible into common stock, at holder’s option, at a 47% discount to the average of the three lowest closing bid prices of the common stock during the 10 trading day period prior to conversion. The Company has identified the embedded derivatives related to the Daniel Notes. These embedded derivatives included certain conversion features and reset provision. (see note 9). The accounting treatment of derivative financial instruments requires that the Company record fair value of the derivatives as of the inception date of Daniel Notes and to fair value as of each subsequent reporting date which at September 30, 2015 was $110,537. At the inception of the Daniel Notes, the Company determined the aggregate fair value of $ 180,930 During the nine months ended September 30, 2015, $75,000 of notes plus accrued interest that were outstanding at December 31, 2014, and $25,000 of notes plus accrued interest that were issued during 2015, were converted into shares of the Company’s common stock (see Note 10). The remaining aggregate Daniel Notes unconverted principle balance as of September 30, 2015 was $75,000. Fourth Man, LLC (During this period) During the nine months ended September 30, 2015, the Company entered into Securities Purchase Agreements with Fourth Man, LLC. (“Fourth Man”), for the sale of a 9.5% convertible notes in the aggregate principal amount of $100,000 (the “Notes”). The Notes bears interest at the rate of 8% to 9.5% per annum. As of the nine months ended September 30, 2015, all interest and principal must be repaid one year from the issuance date, with the last note being due July 31, 2016. The Notes are convertible into shares of common stock, at Fourth Man’s option, at a 47% discount to the lowest closing bid price of the common stock during the 10 trading day period prior to conversion. The Company has identified the embedded derivatives related to the Fourth Man Notes. These embedded derivatives included certain conversion features and reset provision. (see note 9) The accounting treatment of derivative financial instruments requires that the Company record fair value of the derivatives as of the inception date of Fourth Man Notes and to fair value as of each subsequent reporting date which at September 30, 2015 was $108,731. At the inception of the Fourth Man Notes, the Company determined the aggregate fair value of $198,855 of the embedded derivatives. During the nine months ended September 30, 2015, $75,000 of notes plus accrued interest that were outstanding at December 31, 2014, and $25,000 of notes plus accrued interest that were issued during 2015, were converted into shares of the Company’s common stock (see Note 10). The remaining aggregate Fourth Man, LLC Notes unconverted principle balance as of September 30, 2015 was $75,000. Magna Group (During this period) On August 6, 2015, the Company amended the securities purchase agreement with Magna amending the maturity date of its convertible notes payable with Magna from August 7, 2015 to November 7, 2015. This amendment also changes to conversion price of the notes from $0.01035 to the lesser of a) $0.006 or b) a 40% discount from the lowest trading price in the five trading days prior to conversion. The Company has identified the embedded derivatives related to the Magna Notes. These embedded derivatives included certain conversion features and reset provision. The accounting treatment of derivative financial instruments requires that the Company record fair value of the derivatives as of the inception date of Magna Notes and to fair value as of each subsequent reporting date which at September 30, 2015 was $83,787. During the nine months ended September 30, 2015, $140,405 of notes that were outstanding at December 31, 2014, plus accrued interest, were converted into shares of the Company’s common stock (see Note 10). The remaining aggregate Magna notes unconverted principle balance as of September 30, 2015 was $64,595. PowerUp Lending Group, Ltd In July 2015, the Company entered into two revenue based factoring agreements and received an aggregate of $180,000 (less origination fees of $3,590) in exchange for $243,000 of future receipts relating to monies collected from customers or other third party payors. Under the terms of the agreements, the Company is required to make daily payments equal to the greater of $1,464 or 20% of the Company’s daily cash or monetary sales receipts over the term of the agreements (ranging from 126 to 189 business days). The Company has recorded a debt discount which is being amortized to interest expense over the term of the agreements. At September 30. 2015, the Company has recorded interest expense in the amount of $20,014 under the terms of the agreement. The remaining unamortized debt discount at September 30, 2015 is $46,576. Promissory note At December 31, 2014, a related party to one of the Company’s former officers provided notes in aggregate of $1,500,000. As of December 31, 2014, these notes were not considered as related party. The notes range from 4.75% to 8% per annum and are due upon payoff of the Northstar note payable described in Note 8. On June 1, 2015, the Company issued an amended and restated promissory note of $1,697,762 in settlement of the $1,500,000 outstanding subordinated debt (See Note 12), related accrued interest of $373,469 and accumulated and unpaid guarantor fees of $624,737 (See Note 5). The note is unsecured and non-interest bearing with four semi-annual payments of $75,000 beginning on December 31, 2015 with the remaining unpaid balance due June 1, 2020. The Company imputed an interest rate of 5% and discounted the promissory note accordingly. The imputed debt discount of $368,615 is amortized to interest expense using the effective interest method. In connection with the settlement, the Company recorded a gain on settlement of debt of $1,169,058. For the three and nine months ended September 30, 2015, the Company amortized $21,396 and $28,141 of debt discounts to current period operations as interest expense, respectively. Summary: The Company has identified the embedded derivatives related to the Asher, Daniel, Fourth Man LLC and Magna notes. The accounting treatment of derivative financial instruments requires that the Company record fair value of the derivatives as of the inception date of these notes and to fair value as of each subsequent reporting date which at September 30, 2015 was $375,577. The fair value of the embedded derivatives at issuance of the Asher, Daniel, Fourth Man and Magna Notes, was determined using the Binomial Option Pricing Model based on the following assumptions: (1) dividend yield of 0%, (2) expected volatility of 111.98% to 147.97%, (3) weighted average risk-free interest rate of 0.17% to 0.37%, (4) expected lives of 0.75 to 1.00 years, and (5) estimated fair value of the Company’s common stock from $0.0019 to $0.0127 per share. The initial fair value of the embedded debt derivative of $591,360 was allocated as a debt discount up to the proceeds of the notes ($363,964) with the remainder ($227,396) charged to current period operations as interest expense. For the three and nine months ended September 30, 2015, the Company amortized an aggregate of $207,196 and $632,825 of debt discounts to current period operations as interest expense, respectively.

NOTE 8 - RELATED PARTY TRANSACT

NOTE 8 - RELATED PARTY TRANSACTIONS	9 Months Ended
	Sep. 30, 2015
Related Party Transactions [Abstract]
Related Party Transactions Disclosure [Text Block]	NOTE 8 — RELATED PARTY TRANSACTIONS Advances As of September 30, 2015 and December 31, 2014, the Company’s officers and directors have provided advances in the aggregate of $155,363 and $148,759, respectively, for working capital purposes. The advances are unsecured, due on demand and non-interest bearing. Notes payable-related party Northstar Biotechnology Group, LLC On February 29, 2012, a note issued to BlueCrest Master Fund Limited was assigned to Northstar Biotechnology Group, LLC (“Northstar”), owned partly by certain directors and existing shareholders of the Company, including Dr. William P. Murphy Jr., Dr. Samuel Ahn and Charles Hart. At the date of the assignment, the principal amount of the BlueCrest note was $544,267. On March 30, 2012, the Company and Northstar agreed to extend until May 1, 2012 the initial payment date for any and all required monthly under the Note, such that the first of the four monthly payments required under the Note will be due and payable on May, 2012 and all subsequent payments will be due on a monthly basis thereafter commencing on June 1, 2012, and to waive any and all defaults and/or events of default under the Note with respect to such payments. The Company did not make the required payment, and as a result, was in default of the revised agreement The Company renegotiated the terms of the Note and Northstar agreed to suspend the requirement of principal payments by the Company and allow payment of interest-only in common stock. On September 21, 2012, the Company issued 5,000 common stock purchase warrants to Northstar that was treated as additional interest expense upon issuance. On October 1, 2012, the Company and Northstar entered into a limited waiver and forbearance agreement providing a recapitalized new note balance comprised of all sums due Northstar with a maturity date extended perpetually. The Company agreed to issue 5,000,000 shares of Series A Convertible Preferred Stock and 10,000 of common stock in exchange for $210,000 as payment towards outstanding debt, default interest, penalties, professional fees outstanding and due Northstar. In addition, the Company executed a security agreement granting Northstar a lien on all patents, patent applications, trademarks, service marks, copyrights and intellectual property rights of any nature, as well as the results of all clinical trials, know-how for preparing Myoblasts, old and new clinical data, existing approved trials, all right and title to Myoblasts, clinical trial protocols and other property rights. In addition, the Company granted Northstar a perpetual license on products as described for resale, relicensing and commercialization outside the United States. In connection with the granted license, Northstar shall pay the Company a royalty of up to 8% on revenues generated. Effective October 1, 2012, the effective interest rate was 12.85% per annum. The parties agreed, as of February 28, 2013, to reduce the interest rate to 7% per annum. In connection with the consideration paid, Northstar waived, from the effective date through the earlier of termination or expiration of the agreement, satisfaction of the obligations as described in the forbearance agreement. In 2012, 5,000,000 shares of Series A Convertible Preferred Stock were approved to be issued, which was subsequently increased to 20,000,000 shares of preferred stock as Series A Convertible Preferred Stock. In addition, the Company is obligated to issue additional preferred stock equal in lieu of payment of cash of accrued and unpaid interest on each six month anniversary of the effective date (October 1, 2012). In lieu of the initial two payments in preferred stock, the parties have determined to modify the voting rights of the Series A Convertible Preferred Stock from 20 votes per share on matters to be voted on by the common stock holders to 25 votes per share on matters to be voted on by the common stock holders and all prior and subsequent payments of interest will be in common stock. The Company is required to issue additional shares of its common stock (as amended), in lieu of cash, each six month anniversary of the effective date for any accrued and unpaid interest. As described above, during the year ended December 31, 2013, the Company issued the 5,000,000 shares of Series A Convertible Preferred Stock and the 10,000 of common stock described above in exchange for the $210,000 as payment towards outstanding principle of the debt. In addition, the Company issued 15,000,000 shares of Series A Convertible Preferred Stock as a penalty in settlement of the terms of the forbearance agreement. The fair value of the Preferred Stock of $274,050 was included in interest expense for the year ended December 31, 2013. On September 30, 2013, the Company issued 8,772 shares of its common stock as payment of $100,000 towards cash advances. On December 24, 2013, the Company issued 3,916 shares of its common stock as payment of accrued interest through June 30, 2013 of $85,447. On April 2, 2014, the Company issued 275 shares of its common stock in lieu of payment in cash of accrued and unpaid interest of $12,635 due April 1, 2014 per the forbearance agreement. On September 17, 2014, limited waiver and forbearance agreement entered into on October 1, 2012 to provide that the perpetual license on products as described for resale, relicensing and commercialization outside the United States was amended as such to condition upon NorthStar providing certain financing, which financing the Company, in its sole discretion, could decline and retain the license. On October 3, 2014, the Company issued 515 shares of its common stock in lieu of payment in cash of accrued and unpaid interest of $12,705 due October 1, 2014 per the forbearance agreement. On April 3, 2015, the Company issued 1,363 shares of its common stock in lieu of payment in cash of accrued and unpaid interest of $12,635 due April 1, 2015 per the forbearance agreement. As of September 30, 2015 and December 31, 2014, the principle of this note was $362,000. September 30, 2015 December 31, 2014 Notes payable, Dr Murphy $ 465,240 $ 465,240 Note payable, Mr. Tomas 252,250 331,354 Note payable, Mr. Tomas 375,000 375,000 Note payable, Mr. Tomas 500,000 500,000 Note payable, Ms. Comella 287,772 299,465 Total $ 1,880,262 $ 1,971,059 Notes payable, Dr. Murphy At September 30, 2015 and December 31, 2014, the Company has outstanding notes payable to Dr. Murphy with interest at 8% per annum due at maturity in aggregate $465,240. Of the outstanding balance, certain subordinated notes totaling $100,000 and $140,000 were previously due on November 30, 2012 and June 4, 2011 respectively, and are unsecured. The Company is not obligated to make payment until Northstar (or successor) Loan is paid off. Notes payable, Mr. Tomas In 2013, the Company issued a promissory note payable for previous advances and accrued compensation. The promissory note bears interest of 5% per annum and due on demand. During the nine months ended September 30, 2015, the Company paid off $79,104 of the outstanding promissory note. The principle outstanding balance of this note as of September 30, 2015 is $252,250. On August 1, 2013, the Company issued a $375,000 promissory note due on demand in settlement of accrued compensation. The promissory note bears interest of 5% per annum and is due on demand. The principle outstanding balance of this note as of September 30, 2015 is $375,000. On July 1, 2014, the Company issued a $500,000 promissory note in settlement of accrued compensation. The promissory note bears interest of 5% per annum and was due on January 1, 2015. The principle outstanding balance of this note as of September 30, 2015 is $500,000. Notes payable, Ms. Comella On July 1, 2014, the Company issued a $300,000 promissory note in settlement of accrued compensation. The promissory note bears interest of 5% per annum and due on January 1, 2015. During the nine months ended September 30, 2015, the Company paid off $11,693 of the outstanding promissory note. The principle outstanding balance of this note as of September 30, 2015 is $287,772. Transactions with Pavilion During the three and nine months ended September 30, 2015, the Company purchased $69,973 and $242,271 lab kits, respectively, from Pavillion, Inc., a related party, whose owner is related to an officer of the Company.

NOTE 9 - DERIVATIVE LIABILITIES

NOTE 9 - DERIVATIVE LIABILITIES	9 Months Ended
	Sep. 30, 2015
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Instruments and Hedging Activities Disclosure [Text Block]	NOTE 9 — DERIVATIVE LIABILITIES Reset warrants On October 1, 2012, in connection with the forbearance agreement with Northstar as discussed in Note 8 above, the Company issued an aggregate of 15,000 common stock purchase warrants to purchase the Company’s common stock with an exercise price of $0.014 per share for ten years with anti-dilutive (reset) provisions. The Company has identified embedded derivatives related to the issued warrants. These embedded derivatives included certain and anti-dilutive (reset) provisions. The accounting treatment of derivative financial instruments requires that the Company record fair value of the derivatives as of the inception date and to fair value as of each subsequent reporting date. At September 30, 2015, the fair value of the reset provision related to the embedded derivative liability of $23,751 was determined using the Binomial Option Pricing model with the following assumptions: dividend yield: 0%; volatility: 136.32%; risk free rate: 1.74%; and expected life: 7.00 years. The Company recorded a gain on change in derivative liabilities of $58,760 and $126,168 during the three and nine months ended September 30, 2015, respectively. Convertible notes In 2014 and the nine months ended September 30, 2015, the Company issued convertible notes (see Note 7 above). These notes are convertible into common stock, at holders’ option, at a discount to the market price of the Company’s common stock. The Company has identified the embedded derivatives related to these notes relating to certain anti-dilutive (reset) provisions. These embedded derivatives included certain conversion features. The accounting treatment of derivative financial instruments requires that the Company record fair value of the derivatives as of the inception date of these notes and to fair value as of each subsequent reporting date. The fair value of the embedded derivatives at September 30, 2015, in the amount of $375,577, was determined using the Binomial Option Pricing Model based on the following assumptions: (1) dividend yield of 0%; (2) expected volatility of 136.32%, (3) weighted average risk-free interest rate of 0.01 to 0.33%, (4) expected lives of 0.25 to 0.92 years, and (5) estimated fair value of the Company’s common stock of $0.0019 per share. The Company recorded a gain on change in derivative liabilities of $315,924 and $134,784 during the three and nine months ended September 30, 2015, respectively. Based upon ASC 840-15-25 (EITF Issue 00-19, paragraph 11) the Company has adopted a sequencing approach regarding the application of ASC 815-40 to its outstanding convertible notes. Pursuant to the sequencing approach, the Company evaluates its contracts based upon earliest issuance date.

NOTE 10 - STOCKHOLDERS' EQUITY

NOTE 10 - STOCKHOLDERS' EQUITY	9 Months Ended
	Sep. 30, 2015
Stockholders' Equity Note [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	NOTE 10 — STOCKHOLDERS’ EQUITY On October 12, 2015, the Company filed an amendment to its Articles of Incorporation and effected a 1-for-1,000 reverse stock split of its issued and outstanding shares of common stock, $0.001 par value, effective November 19, 2015. The Financial Industry Regulatory Authority (“FINRA”) declared the ex-dividend date for the dividend date as November 4, 2015. split as if it had occurred on the first day of the first period presented During the nine months ended September 30, 2015, the Company issued an aggregate of 20,819 shares of its common stock in the amount of $152,777 for the settlement of outstanding accounts payable and accrued expenses. In connection with the issuance of the shares the Company recognized a gain on settlement of accounts payable and accrued expenses in the amount of $86,763 (see Note 5). During the nine months ended September 30, 2015, the Company issued 6,650 shares of common stock in settlement of litigation. In connection with the issuances, the Company recognized a loss in the amount of $59,850, which is included in the marketing, general and administration expense in the Statement of Operations (see Note 12). On April 3, 2015, the Company issued 1,363 shares of its common stock in lieu of payment in cash of accrued and unpaid interest of $12,635 due April 1, 2015 per the forbearance agreement on Northstar note (See Note 8). During the nine months ended September 30, 2015, the Company issued an aggregate of 247,524 shares of its common stock for the conversion of $623,237 of notes payable and related accrued interest. Upon conversion of the notes, the Company recorded an adjustment to the derivative liability in the amount of $672,350 (see Note 13). During the nine months ended September 30, 2015, the Company purchased 37,852 shares of the Company’s common stock in the open market at an average cost of $4.17 per share. During the nine months ended September 30, 2015, the Company issued an aggregate of 87,812 shares of common stock in exchange for $521,538 under the stock purchase agreement with Magna Equities II, LLC (see Note 6), and issued an aggregate of 7,852 shares of common stock in exchange for $61,270. In connection with the stock sale, the Company issued an aggregate of 1,443,656 warrants to purchase the Company’s common stock (see Note 11). During the nine months ended September 30, 2015, the Company issued an aggregate of 24,353 shares of its common stock in settlement of accumulative outstanding accounts payable due to Guarantors of the Company of $961,125. In connection with the issuance, the Company incurred a $791,024 gain in settlement of debt.

NOTE 11 - STOCK OPTIONS AND WAR

NOTE 11 - STOCK OPTIONS AND WARRANTS	9 Months Ended
	Sep. 30, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	NOTE 11 — STOCK OPTIONS AND WARRANTS Stock Options In December 1999, the Board of Directors and shareholders adopted the 1999 Officers and Employees Stock Option Plan, or the Employee Plan, and the 1999 Directors and Consultants Stock Option Plan, or the Director Plan. The Employee Plan and the Director Plan are collectively referred to herein as the Plans. The Plans are administered by the Board of Directors and the Compensation Committee. The objectives of the Plans include attracting and retaining key personnel by encouraging stock ownership in the Company by such persons. In February 2010, the Directors & Consultants Plan was amended to extend the termination date of the Plan to December 1, 2011. On April 1, 2013, the Board of Directors approved, subject to shareholder approval, the establishment of the Bioheart 2013 Omnibus Equity Compensation Plan, or the “2013 Omnibus Plan”. The 2013 Omnibus Plan reserves up to fifty thousand shares of common stock for issuance. On August 4, 2014, the Board of Directors approved to set the reserve to one hundred thousand shares of common stock for issuance and to close the 1999 Officers and Employees Stock Option Plan. On February 2, 2015, at the annual meeting of shareholders, the majority of shareholders approved the 2013 Omnibus Equity Compensation Plan. On November 2, 2015, the Board of Directors approved the increase of the reserve under the 2013 Omnibus Plan to (pre-split) five hundred million shares of common stock for issuance. A summary of options at September 30, 2015 and activity during the nine months then ended is presented below: Shares Weighted- Average Exercise Price Weighted- Average Remaining Contractual Term (in years) Options outstanding at January 1, 2014 23,921 $ 150.00 9.0 Granted 43,148 $ 23.00 10.0 Exercised — $ Forfeited/Expired (136 ) $ 5,200.00 Options outstanding at December 31, 2014 66,933 $ 56.00 8.9 Granted 7,100 $ 11.16 10.0 Exercised — Forfeited/Expired (229 ) $ 5,112.48 Options outstanding at September 30, 2015 73,804 $ 36.32 8.3 Options exercisable at September 30, 2015 44,468 $ 46.41 8.3 Available for grant at September 30, 2015 89,400 The following information applies to options outstanding and exercisable at September 30, 2015: Options Outstanding Options Exercisable Shares Weighted- Average Remaining Contractual Term Weighted- Average Exercise Price Shares Weighted- Average Exercise Price $ 0.00 – $20.00 52,690 8.2 $ 16.73 34,490 $ 16.38 $ 20.01 – $30.00 19,849 8.8 $ 26.96 8,713 $ 26.94 $ 30.01 – $100.00 300 5.9 $ 70.00 300 $ 70.00 $ >100.00 965 4.3 $ 1,243.27 965 $ 1,243.27 73,804 8.3 $ 36.32 44,468 $ 46.41 On February 2, 2015, the Company issued an aggregate 7,000 options to purchase the Company’s common stock at $11.16 per share to members of the Board of Directors, vesting immediately and exercisable over 10 years. The aggregate fair value of $121,735, determined using the Black Scholes option pricing model with the following assumptions: Dividend yield: 0%; Volatility: 142.65% and Risk free rate: 1.68%. On August 24, 2015, the Company issued 100 options to purchase the Company’s common stock at $5.31 per share to a consultant, vesting immediately and exercisable over 4 years. The aggregate fair value of $347, determined using the Black Scholes option pricing model with the following assumptions: Dividend yield: 0%; Volatility: 129.01% and Risk free rate: 1.39%. The fair value of all options vesting during the three and nine months ended September 30, 2015 of $73,520 and $345,761, respectively, was charged to current period operations. The fair value of all options vesting during the three and nine months ended September 30, 2014 of $164,247 and $407,616, respectively, was charged to period operations. Warrants A summary of common stock purchase warrants at September 30, 2015 and activity during the period then ended is presented below: Shares Weighted- Average Exercise Price Weighted- Average Remaining Contractual Term (in years) Outstanding at January 1, 2014 118,134 $ 220.00 6.3 Issued 57,582 $ 20.00 8.2 Exercised (11,918 ) $ 10.00 Expired (13,178 ) $ 80.00 Outstanding at December 31, 2014 150,620 $ 10.00 6.6 Issued 1,444 $ 11.27 10.0 Exercised $ Expired (13,325 ) $ 24.00 Outstanding at September 30, 2015 138,739 $ 182.90 6.5 Exercisable at September 30, 2015 133,194 $ 100.27 6.6 The following information applies to common stock purchase warrants outstanding and exercisable at September 30, 2015: Warrants Outstanding Warrants Exercisable Shares Weighted- Average Remaining Contractual Term Weighted- Average Exercise Price Shares Weighted- Average Exercise Price $ 0.01 – $20.00 94,108 7.0 $ 15.54 94,108 $ 15.54 $ 20.01 – $30.00 29,743 6.3 $ 24.52 27,743 $ 24.72 $ 30.01 – $50.00 6,253 3.4 $ 48.36 4,253 $ 48.49 $ 50.01 – $60.00 543 2.2 $ 60.00 543 $ 60.00 $ >60.00 8,092 4.4 $ 2,823.67 6,547 $ 1,675.28 138,739 6.5 $ 182.90 133,194 $ 100.27 In conjunction with the authorized issuance of common stock, the Company granted 1,444 common stock purchase warrants during the nine months ended September 30, 2015. The warrants are exercisable at an exercise price of approximately $11.27 per share for ten years.

NOTE 12 - COMMITMENTS AND CONTI

NOTE 12 - COMMITMENTS AND CONTINGENCIES	9 Months Ended
	Sep. 30, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	NOTE 12 — COMMITMENTS AND CONTINGENCIES Litigation On March 19 2015, the Company settled a prospective dispute with a third party over the use of proprietary information through the issuance of 6,650 shares of common stock. (See Note 10) On November 10, 2014, the Company was served with a lawsuit by an alleged assignee and a guarantor to a Loan Guarantee, Payment and Security Agreement. These parties claim breach of that Agreement and damages of approximately $2.3 Million plus interest. The assignor and assignee also sued the Company’s directors and two past directors and an affiliate shareholder for breach of fiduciary duty, claiming damages as alleged creditors arising out of these parties’ alleged participation in Northstar Biotech Group, LLC, a secured creditor of the Company. On June 1, 2015, the Company settled the lawsuit. As part of the settlement, the Company recorded a gain of $1,169,058. The Company provided a note to the original guarantor in the amount of $1,697,762, to be paid over a five year period with a 0% interest rate. The Company is subject to other legal proceedings that arise in the ordinary course of business. In the opinion of management, as of September 30, 2015, the amount of ultimate liability with respect to such matters, if any, in excess of applicable insurance coverage, is not likely to have a material impact on the Company’s business, financial position, results of operations or liquidity. However, as the outcome of litigation and other claims is difficult to predict significant changes in the estimated exposures could exist.

NOTE 13 - FAIR VALUE MEASUREMEN

NOTE 13 - FAIR VALUE MEASUREMENT	9 Months Ended
	Sep. 30, 2015
Fair Value Disclosures [Abstract]
Fair Value Disclosures [Text Block]	NOTE 13 — FAIR VALUE MEASUREMENT The Company adopted the provisions of Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”) on January 1, 2008. ASC 825-10 defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required or permitted to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact and considers assumptions that market participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions, and risk of nonperformance. ASC 825-10 establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 825-10 establishes three levels of inputs that may be used to measure fair value: Level 1 – Quoted prices in active markets for identical assets or liabilities. Level 2 – Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which all significant inputs are observable or can be derived principally from or corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 – Unobservable inputs to the valuation methodology that are significant to the measurement of fair value of assets or liabilities. All items required to be recorded or measured on a recurring basis are based upon level 3 inputs. To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for disclosure purposes, the level in the fair value hierarchy within which the fair value measurement is disclosed and is determined based on the lowest level input that is significant to the fair value measurement. Upon adoption of ASC 825-10, there was no cumulative effect adjustment to beginning retained earnings and no impact on the financial statements. The carrying value of the Company’s cash and cash equivalents, accounts receivable, accounts payable, short-term borrowings (including convertible notes payable), and other current assets and liabilities approximate fair value because of their short-term maturity. As of September 30, 2015 or December 31, 2014, the Company did not have any items that would be classified as level 1 or 2 disclosures. The Company recognizes its derivative liabilities as level 3 and values its derivatives using the methods discussed in notes 7 and 9. While the Company believes that its valuation methods are appropriate and consistent with other market participants, it recognizes that the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different estimate of fair value at the reporting date. The primary assumptions that would significantly affect the fair values using the methods discussed in Notes 7 and 9 are that of volatility and market price of the underlying common stock of the Company. As of September 30, 2015 and December 31, 2014, the Company did not have any derivative instruments that were designated as hedges. The derivative liability as of September 30, 2015, in the amount of $399,328 has a level 3 classification. The following table provides a summary of changes in fair value of the Company’s Level 3 financial liabilities as of September 30, 2015: Warrant Liability Debt Derivative Balance, December 31, 2013 146,855 $ 256,956 Total (gains) losses Initial fair value of debt derivative at note issuance — 1,443,708 Initial fair value of derivative relating to reset warrants — — Mark-to-market at December 31, 2014: 3,065 (429,018 ) Transfers out of Level 3 upon increase in authorized shares — — Transfers out of Level 3 upon conversion and settlement of notes — (680,295 ) Balance, December 31, 2014 $ 149,920 $ 591,351 Total (gains) losses Initial fair value of debt derivative at note issuance — 591,360 Mark-to-market at September 30, 2015: (126,169 ) (134,784 ) Transfers out of Level 3 upon conversion or payoff of notes payable — (672,350 ) Balance, September 30, 2015 $ 23,751 $ 375,577 Net gain for the period included in earnings relating to the liabilities held at September 30, 2015 $ 126,169 $ 134,784 Fluctuations in the Company’s stock price are a primary driver for the changes in the derivative valuations during each reporting period. The Company’s stock price decreased approximately 82% from December 31, 2014 to September 30, 2015. As the stock price decreases for each of the related derivative instruments, the value to the holder of the instrument generally decreases.. Additionally, stock price volatility is one of the significant unobservable inputs used in the fair value measurement of each of the Company’s derivative instruments. The estimated fair value of these liabilities is sensitive to changes in the Company’s expected volatility. Increases in expected volatility would generally result in a higher fair value measurement.

NOTE 14 - SUBSEQUENT EVENTS

NOTE 14 - SUBSEQUENT EVENTS	9 Months Ended
	Sep. 30, 2015
Subsequent Events [Abstract]
Subsequent Events [Text Block]	NOTE 14 — SUBSEQUENT EVENTS Subsequent stock issuances In October and November 2015, the Company issued an aggregate of 252,157 shares of its common stock in settlement of $136,095 of outstanding convertible notes payable and $7,499 accrued interest; 14,848 shares of its common stock in settlement of services of approximately $65,015. In addition, the Company issued an aggregate 38,678 shares of its common stock in settlement of $100,000 principal and $12,705 accrued interest on Northstar debt. The Company also issued an aggregate of 274,211 shares of its common stock in settlement of $471,000 of outstanding notes payable and advances to related parties. Subsequent financing On October 1, 2015, the Company entered into a Securities Purchase Agreement with Magna Equities, II, LLC for the sale of 12% convertible note in the principal amount of $160,000 (the “Note”). The Note bears interest at the rate of 12% per annum. All interest and principal must be repaid on August 1, 2016. The Note is convertible into common stock, at Magna Equities, II, LLC’s option, at a $0.72 per share or if a registration statement registering the underlying shares of common stock is not filed within 70 days, 45% of the lowest trading price during five consecutive trading days prior to conversion with anti-dilutive provisions. On October 7, 2015, the Company entered into a Securities Purchase Agreement with Fourth Man, LLC., for the sale of a 9.5% convertible note in the principal amount of $25,000 (the “Note”). The Note bears interest at the rate of 9.5% per annum. All interest and principal must be repaid on October 6, 2016. The Note is convertible into common stock, at Fourth Man’s option, at a 47% discount to the lowest daily closing trading price of the common stock during the 10 trading day period prior to conversion. In the event the Company prepays the Note in full, the Company is required to pay off all principal at 150%, interest and any other amounts. The Company amended its Articles of Incorporation to change its name to U.S. Stem Cell, Inc. and to implement a reverse stock split in the ratio of 1 share for every 1,000 shares of common stock. This amendment was approved and filed of record by the Florida Secretary of State on October 12, 2015, effective on October 19, 2015. FINRA has declared the Company’s 1-for-1,000 reverse stock split market effective as of November 4, 2015. The number of authorized shares of common and preferred stock remained unchanged. All fractional shares will be rounded up. In addition, the ticker symbol will be BHRTD for 20 business days on November 4 th 2015 and will change to USRM (OTC Markets) on December 2, 2015.

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	9 Months Ended
	Sep. 30, 2015
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis and business presentation U.S. Stem Cell, Inc. (f.k.a. Bioheart, Inc.) (the “Company”) was incorporated under the laws of the State of Florida in August, 1999. The Company is in the cardiovascular sector of the cell technology industry delivering cell therapies and biologics that help address congestive heart failure, lower limb ischemia, chronic heart ischemia, acute myocardial infarctions and other issues. The business includes the development of proprietary cell therapy products as well as revenue generating physician and patient based regenerative medicine/cell therapy training services, cell collection and cell storage services, the sale of cell collection and treatment kits for humans and animals, and the operation of a cell therapy clinic. To date, the Company has not generated significant sales revenues in that they remain less than their total operating expenses, has incurred expenses, and has sustained losses. Consequently, its operations are subject to all the risks inherent in the establishment of a research and development business enterprise. On October 12, 2015, the Company amended its Articles of Incorporation to change its name to U.S. Stem Cell, Inc. and to implement a reverse stock split in the ratio of 1 share for every 1,000 shares of common stock. This amendment was approved and filed of record by the Florida Secretary of State on October 12, 2015, effective on October 19, 2015. FINRA has declared the Company’s 1-for-1,000 reverse stock split market effective as of November 4, 2015. In addition, the ticker symbol will be BHRTD for 20 business days from November 4 th . These financial statements have been retroactively restated to reflect the reverse stock split (see note 10).
Revenue Recognition, Policy [Policy Text Block]	Revenue Recognition The Company recognizes revenue in accordance with Accounting Standards Codification subtopic 605-10, Revenue Recognition (“ASC 605-10”) which requires that four basic criteria must be met before revenue can be recognized: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred; (3) the selling price is fixed and determinable; and (4) collectability is reasonably assured. Determination of criteria (3) and (4) are based on management’s judgments regarding the fixed nature of the selling prices of the products delivered and the collectability of those amounts. Provisions for discounts and rebates to customers, estimated returns and allowances, and other adjustments are provided for in the same period the related sales are recorded. At the time of each transaction, management assesses whether the fee associated with the transaction is fixed or determinable and whether or not collection is reasonably assured. The assessment of whether the fee is fixed or determinable is based upon the payment terms of the transaction. Collectability is assessed based on a number of factors, including past transaction history with the client and the creditworthiness of the client. Revenues for test kits and equipment sold are not recorded until test kits are delivered. The Company has revenue sharing arrangements for the sale of goods whereby the Company is the primary obligor, sets pricing with the customers and bears all associated credit risks with the customers. Sales under revenue share arrangements are recorded as gross sales and any portion shared with third parties under such arrangements are classified as selling expense due to the nature of the marketing activities performed by the third party. Revenues from trainings are not recorded until the completion of the training. Any cash received as a deposit for trainings are recorded by the company as a liability. Patent treatments and laboratory services revenue are recognized when those services have been completed or satisfied. Revenues for bank sales are accounted for as Multiple-Element Arrangements under ASC 605-10 which incorporates Accounting Standards Codification subtopic 605-25, Multiple-Element Arrangements (“ASC 605-25”). ASC 605-25 addresses accounting for arrangements that may involve the delivery or performance of multiple products, services and/or rights to use assets. At September 30, 2015 and December 31, 2014, the Company had deferred revenues of $32,170 and $-0-, respectively.
Receivables, Policy [Policy Text Block]	Accounts Receivable Trade receivables are carried at their estimated collectible amounts. Trade credit is generally extended on a short-term basis; thus trade receivables do not bear interest. Trade accounts receivable are periodically evaluated for collectability based on past credit history with customers and their current financial condition.
Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]	Allowance for Doubtful Accounts Any changes to the allowance for doubtful accounts on accounts receivable are changed to operations in amounts sufficient to maintain the allowance for uncollectible accounts at a level management believes is adequate to cover any probable losses. Management determines the adequacy of the allowance based on historical write-off percentages and the current status of accounts receivable. Accounts receivable are charged off against the allowance when collectability is determined to be permanently impaired. As of September 30, 2015 and December 31, 2014, allowance for doubtful accounts was $-0-.
Equity Method Investments, Policy [Policy Text Block]	Investments The Company has adopted Accounting Standards Codification subtopic 323-10, Investments-Equity Methods and Joint Ventures (“ASC 323-10) which requires the accounting for investments where the Company can exert significant influence, but not control of a joint venture or equity investment. The Company accounted for its 33 percent ownership of U.S. Stem Cell Clinic, LLC utilizing the equity method of accounting.
Earnings Per Share, Policy [Policy Text Block]	Net Loss per Common Share, basic and diluted The Company has adopted Accounting Standards Codification subtopic 260-10, Earnings Per Share (“ASC 260-10”) specifying the computation, presentation and disclosure requirements of earnings per share information. Basic loss per share has been calculated based upon the weighted average number of common shares outstanding. Shares issuable upon conversion of convertible debt, stock options and warrants have been excluded as common stock equivalents in the diluted loss per share for the three and nine months ended September 30, 2015 and 2014 because their effect is anti-dilutive on the computation. Fully diluted shares outstanding were 1,206,554 and 659,543 for the three months ended September 30, 2015 and 2014, respectively and 1,107,710 and 605,016 for the nine months ended September 30, 2015 and 2014, respectively.
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	Stock based compensation The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. For employees and directors, the fair value of the award is measured on the grant date and for non-employees, the fair value of the award is generally re-measured on vesting dates and interim financial reporting dates until the service period is complete. The fair value amount is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period. Stock-based compensation expense is recorded by the Company in the same expense classifications in the statements of operations, as if such amounts were paid in cash. As of September 30, 2015, there were outstanding stock options to purchase 73,804 shares of common stock, 44,468 shares of which were vested.
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentrations of Credit Risk The Company’s financial instruments that are exposed to a concentration of credit risk are cash and accounts receivable. Generally, the Company’s cash and cash equivalents in interest-bearing accounts does not exceed FDIC insurance limits. The financial stability of these institutions is periodically reviewed by senior management. As of September 30, 2015, five customers represented 15%, 5%, 7%, 15% and 14% respectively for an aggregate of 56% of the Company’s accounts receivable. As of December 31, 2014, two customers represented 38% and 17%, for an aggregate of 55%, of the Company’s accounts receivable. For the three months ended September 30, 2015, the Company’s revenues earned from the sale of products and services were $557,612, of which one customer represented 11% of the Company’s revenues. For the three months ended September 30, 2014, the Company’s revenues earned from the sale of products and services were $579,536, of which no customers represented 10% or more of the Company’s revenues. For the nine months ended September 30, 2015, the Company’s revenues earned from the sale of products and services were $1,612,476, of which no customers represented 10% or more of the Company’s revenues. For the nine months ended September 30, 2014, the Company’s revenues earned from the sale of products and services were $1,563,864, of which one customer represented 11% of the Company’s revenues.
Research and Development Expense, Policy [Policy Text Block]	Research and Development The Company accounts for research and development costs in accordance with Accounting Standards Codification subtopic 730-10, Research and Development (“ASC 730-10”). Under ASC 730-10, all research and development costs must be charged to expense as incurred. Accordingly, internal research and development costs are expensed as incurred. Third-party research and development costs are expensed when the contracted work has been performed or as milestone results have been achieved as defined under the applicable agreement. Company-sponsored research and development costs related to both present and future products are expensed in the period incurred. The Company incurred research and development expenses of $12,764 and $39,696 for the three and nine months ended September 30, 2015, respectively; and $8,581 and $33,916 for the three and nine months ended September 30, 2014, respectively.
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair Value Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”) requires disclosure of the fair value of certain financial instruments. The carrying value of cash and cash equivalents, accounts payable and accrued liabilities, and short-term borrowings, as reflected in the balance sheets, approximate fair value because of the short-term maturity of these instruments. All other significant financial assets, financial liabilities and equity instruments of the Company are either recognized or disclosed in the financial statements together with other information relevant for making a reasonable assessment of future cash flows, interest rate risk and credit risk. Where practicable the fair values of financial assets and financial liabilities have been determined and disclosed; otherwise only available information pertinent to fair value has been disclosed. The Company follows Accounting Standards Codification subtopic 820-10, Fair Value Measurements and Disclosures (“ASC 820-10”) and Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”), which permits entities to choose to measure many financial instruments and certain other items at fair value.
Derivatives, Policy [Policy Text Block]	Derivative Instrument Liability The Company accounts for derivative instruments in accordance with ASC 815, which establishes accounting and reporting standards for derivative instruments and hedging activities, including certain derivative instruments embedded in other financial instruments or contracts and requires recognition of all derivatives on the balance sheet at fair value, regardless of hedging relationship designation. Accounting for changes in fair value of the derivative instruments depends on whether the derivatives qualify as hedge relationships and the types of relationships designated are based on the exposures hedged. At September 30, 2015 and December 31, 2014, the Company did not have any derivative instruments that were designated as hedges. At September 30, 2015 and December 31, 2014, the Company had outstanding convertible notes that contained embedded derivatives. These embedded derivatives include certain conversion features and reset provisions. (See Note 7 and Note 9)
Reliance on Key Personnel and Consultants [Policy Text Block]	Reliance on Key Personnel and Consultants The Company has four full-time employees and one part-time employee. The Company is heavily dependent on the continued active participation of its two current executive officers, one employee and key consultants. The loss of any of the senior management or key consultants could significantly and negatively impact the business until adequate replacements can be identified and put in place.
Reclassification, Policy [Policy Text Block]	Reclassification Certain reclassifications have been made to prior periods’ data to conform with the current year’s presentation. These reclassifications had no effect on reported income or losses.
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements There were various updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on the Company’s financial position, results of operations or cash flows.

NOTE 4 - PROPERTY AND EQUIPME23

NOTE 4 - PROPERTY AND EQUIPMENT (Tables)	9 Months Ended
	Sep. 30, 2015
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment [Table Text Block]	Property and equipment as of September 30, 2015 and December 31, 2014 summarized as follows: September 30, 2015 December 31, 2014 Laboratory and medical equipment $ 353,252 $ 352,358 Furniture, fixtures and equipment 125,634 125,634 Computer equipment 47,647 47,647 Leasehold improvements 362,046 362,046 888,579 887,685 Less accumulated depreciation and amortization (878,946 ) (874,999 ) $ 9,633 $ 12,686

NOTE 5 - ACCRUED EXPENSES (Tabl

NOTE 5 - ACCRUED EXPENSES (Tables)	9 Months Ended
	Sep. 30, 2015
Payables and Accruals [Abstract]
Schedule of Accrued Liabilities [Table Text Block]	Accrued expenses consisted of the following as of September 30, 2015 and December 31, 2014: September 30, 2015 December 31, 2014 Amounts payable to the Guarantors of the Company’s loan agreement with Bank of America and Seaside Bank, including fees and interest $ 40,205 $ 1,533,217 Interest payable on notes payable 451,937 685,575 Vendor accruals and other 141,582 120,836 Employee commissions, compensation, etc. 22,417 33,987 $ 656,141 $ 2,373,615

NOTE 7 - NOTES PAYABLE (Tables)

NOTE 7 - NOTES PAYABLE (Tables)	9 Months Ended
	Sep. 30, 2015
Debt Disclosure [Abstract]
Schedule of Debt [Table Text Block]	Notes payable were comprised of the following as of September 30, 2015 and December 31, 2014: September 30, 2015 December 31, 2014 Seaside Bank note payable. $ 980,000 $ 980,000 Hunton & Williams notes payable 384,972 384,972 Asher notes payable 66,000 151,000 Daniel James Management notes payable 75,000 75,000 Fourth Man, LLC notes payable 75,000 75,000 Magna Group note payable 64,595 205,000 Power Up Lending Group notes payable 169,965 - Total notes payable 1,815,532 1,870,972 Less unamortized debt discount (180,032 ) (339,160 ) Total notes payable net of unamortized debt discount $ 1,635,500 $ 1,531,812

NOTE 8 - RELATED PARTY TRANSA26

NOTE 8 - RELATED PARTY TRANSACTIONS (Tables)	9 Months Ended
	Sep. 30, 2015
Related Party Transactions [Abstract]
Schedule of Related Party Transactions [Table Text Block]	September 30, 2015 December 31, 2014 Notes payable, Dr Murphy $ 465,240 $ 465,240 Note payable, Mr. Tomas 252,250 331,354 Note payable, Mr. Tomas 375,000 375,000 Note payable, Mr. Tomas 500,000 500,000 Note payable, Ms. Comella 287,772 299,465 Total $ 1,880,262 $ 1,971,059

NOTE 11 - STOCK OPTIONS AND W27

NOTE 11 - STOCK OPTIONS AND WARRANTS (Tables)	9 Months Ended
	Sep. 30, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	A summary of options at September 30, 2015 and activity during the nine months then ended is presented below: Shares Weighted- Average Exercise Price Weighted- Average Remaining Contractual Term (in years) Options outstanding at January 1, 2014 23,921 $ 150.00 9.0 Granted 43,148 $ 23.00 10.0 Exercised — $ Forfeited/Expired (136 ) $ 5,200.00 Options outstanding at December 31, 2014 66,933 $ 56.00 8.9 Granted 7,100 $ 11.16 10.0 Exercised — Forfeited/Expired (229 ) $ 5,112.48 Options outstanding at September 30, 2015 73,804 $ 36.32 8.3 Options exercisable at September 30, 2015 44,468 $ 46.41 8.3 Available for grant at September 30, 2015 89,400
Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]	The following information applies to options outstanding and exercisable at September 30, 2015: Options Outstanding Options Exercisable Shares Weighted- Average Remaining Contractual Term Weighted- Average Exercise Price Shares Weighted- Average Exercise Price $ 0.00 – $20.00 52,690 8.2 $ 16.73 34,490 $ 16.38 $ 20.01 – $30.00 19,849 8.8 $ 26.96 8,713 $ 26.94 $ 30.01 – $100.00 300 5.9 $ 70.00 300 $ 70.00 $ >100.00 965 4.3 $ 1,243.27 965 $ 1,243.27 73,804 8.3 $ 36.32 44,468 $ 46.41
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	A summary of common stock purchase warrants at September 30, 2015 and activity during the period then ended is presented below: Shares Weighted- Average Exercise Price Weighted- Average Remaining Contractual Term (in years) Outstanding at January 1, 2014 118,134 $ 220.00 6.3 Issued 57,582 $ 20.00 8.2 Exercised (11,918 ) $ 10.00 Expired (13,178 ) $ 80.00 Outstanding at December 31, 2014 150,620 $ 10.00 6.6 Issued 1,444 $ 11.27 10.0 Exercised $ Expired (13,325 ) $ 24.00 Outstanding at September 30, 2015 138,739 $ 182.90 6.5 Exercisable at September 30, 2015 133,194 $ 100.27 6.6
Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Table Text Block]	The following information applies to common stock purchase warrants outstanding and exercisable at September 30, 2015: Warrants Outstanding Warrants Exercisable Shares Weighted- Average Remaining Contractual Term Weighted- Average Exercise Price Shares Weighted- Average Exercise Price $ 0.01 – $20.00 94,108 7.0 $ 15.54 94,108 $ 15.54 $ 20.01 – $30.00 29,743 6.3 $ 24.52 27,743 $ 24.72 $ 30.01 – $50.00 6,253 3.4 $ 48.36 4,253 $ 48.49 $ 50.01 – $60.00 543 2.2 $ 60.00 543 $ 60.00 $ >60.00 8,092 4.4 $ 2,823.67 6,547 $ 1,675.28 138,739 6.5 $ 182.90 133,194 $ 100.27

NOTE 13 - FAIR VALUE MEASUREM28

NOTE 13 - FAIR VALUE MEASUREMENT (Tables)	9 Months Ended
	Sep. 30, 2015
Fair Value Disclosures [Abstract]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	The following table provides a summary of changes in fair value of the Company’s Level 3 financial liabilities as of September 30, 2015: Warrant Liability Debt Derivative Balance, December 31, 2013 146,855 $ 256,956 Total (gains) losses Initial fair value of debt derivative at note issuance — 1,443,708 Initial fair value of derivative relating to reset warrants — — Mark-to-market at December 31, 2014: 3,065 (429,018 ) Transfers out of Level 3 upon increase in authorized shares — — Transfers out of Level 3 upon conversion and settlement of notes — (680,295 ) Balance, December 31, 2014 $ 149,920 $ 591,351 Total (gains) losses Initial fair value of debt derivative at note issuance — 591,360 Mark-to-market at September 30, 2015: (126,169 ) (134,784 ) Transfers out of Level 3 upon conversion or payoff of notes payable — (672,350 ) Balance, September 30, 2015 $ 23,751 $ 375,577 Net gain for the period included in earnings relating to the liabilities held at September 30, 2015 $ 126,169 $ 134,784

NOTE 1 - SIGNIFICANT ACCOUNTI29

NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($)	Oct. 12, 2015	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014	Dec. 31, 2012
NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Deferred Revenue, Current (in Dollars)		$ 32,170		$ 32,170		$ 0
Allowance for Doubtful Accounts Receivable, Current (in Dollars)		$ 0		$ 0		$ 0
Weighted Average Number of Shares Outstanding, Diluted (in Shares)		1,206,554	659,543	1,107,710	605,016
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number (in Shares)		73,804		73,804		66,933	23,921
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number (in Shares)		44,468		44,468
Revenue, Net (in Dollars)		$ 557,612	$ 579,536	$ 1,612,476	$ 1,563,864
Research and Development Expense (in Dollars)		$ 12,764	$ 8,581	$ 39,696	$ 33,916
Subsequent Event [Member]
NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Stockholders' Equity Note, Stock Split	1-for-1,000
U.S. Stem Cell Clinic, LLC [Member]
NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Equity Method Investment, Ownership Percentage		33.00%		33.00%
Full-Time Employees [Member]
NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Number of Employees				4
Part-Time Employees [Member]
NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Number of Employees				1
Accounts Receivable [Member] | Credit Concentration Risk [Member]
NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Concentration Risk, Percentage				56.00%		55.00%
Accounts Receivable [Member] | Credit Concentration Risk [Member] | Customer One [Member]
NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Concentration Risk, Percentage				15.00%		38.00%
Accounts Receivable [Member] | Credit Concentration Risk [Member] | Customer Two [Member]
NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Concentration Risk, Percentage				5.00%		17.00%
Accounts Receivable [Member] | Credit Concentration Risk [Member] | Customer Three [Member]
NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Concentration Risk, Percentage				7.00%
Accounts Receivable [Member] | Credit Concentration Risk [Member] | Customer Four [Member]
NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Concentration Risk, Percentage				15.00%
Accounts Receivable [Member] | Credit Concentration Risk [Member] | Customer Five [Member]
NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Concentration Risk, Percentage				14.00%
Sales Revenue, Goods, Net [Member] | Customer Concentration Risk [Member] | Customer One [Member]
NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Concentration Risk, Percentage		11.00%			11.00%

NOTE 2 - GOING CONCERN MATTERS

NOTE 2 - GOING CONCERN MATTERS (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Operating Income (Loss)	$ (264,096)	$ (1,466,732)	$ (1,551,966)	$ (2,545,703)
Net Cash Provided by (Used in) Operating Activities			(789,462)	$ (747,184)
Working Capital (Deficit)	$ (7,500,000)		$ (7,500,000)

NOTE 3 - INVESTMENTS (Details)

NOTE 3 - INVESTMENTS (Details) - USD ($)	3 Months Ended		9 Months Ended		193 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Dec. 31, 2014
NOTE 3 - INVESTMENTS (Details) [Line Items]
Payments for (Proceeds from) Investments			$ 10,000	$ 0
Income (Loss) from Equity Method Investments	$ 11,625	$ 0	23,934	$ 0
Investments	$ 74,530		$ 74,530		$ 74,530	$ 40,597
U.S. Stem Cell Clinic, LLC [Member]
NOTE 3 - INVESTMENTS (Details) [Line Items]
Equity Method Investment, Ownership Percentage	33.00%		33.00%		33.00%
Payments for (Proceeds from) Investments			$ 59,714
Income (Loss) from Equity Method Investments	$ 11,625		$ 23,934		$ 14,816

NOTE 4 - PROPERTY AND EQUIPME32

NOTE 4 - PROPERTY AND EQUIPMENT (Details) - Schedule of Property and Equipment - USD ($)	Sep. 30, 2015	Dec. 31, 2014
Schedule of Property and Equipment [Abstract]
Laboratory and medical equipment	$ 353,252	$ 352,358
Furniture, fixtures and equipment	125,634	125,634
Computer equipment	47,647	47,647
Leasehold improvements	362,046	362,046
	888,579	887,685
Less accumulated depreciation and amortization	(878,946)	(874,999)
	$ 9,633	$ 12,686

NOTE 5 - ACCRUED EXPENSES (Deta

NOTE 5 - ACCRUED EXPENSES (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
NOTE 5 - ACCRUED EXPENSES (Details) [Line Items]
Gains (Losses) on Extinguishment of Debt	$ 58,873	$ 85,229	$ 2,097,483	$ 2,272,283
Common Stock Issued in Settlement of Accounts Payable, Accrued Expenses and Accrued Interest [Member]
NOTE 5 - ACCRUED EXPENSES (Details) [Line Items]
Debt Conversion, Converted Instrument, Shares Issued (in Shares)			20,819	45,232
Gains (Losses) on Extinguishment of Debt			$ 86,763	$ 105,737
Common Stock Issued in Settlement of Guarantor Fees [Member]
NOTE 5 - ACCRUED EXPENSES (Details) [Line Items]
Debt Conversion, Converted Instrument, Shares Issued (in Shares)			24,353
Gains (Losses) on Extinguishment of Debt			$ 791,024
Debt Conversion, Converted Instrument, Amount			$ 961,124
Debt Instrument, Term			5 years
Extinguishment of Debt, Amount			$ 624,737
Relief of Accounts Payable [Member]
NOTE 5 - ACCRUED EXPENSES (Details) [Line Items]
Gains (Losses) on Extinguishment of Debt			$ 50,638

NOTE 5 - ACCRUED EXPENSES (De34

NOTE 5 - ACCRUED EXPENSES (Details) - Schedule of Accrued Liabilities - USD ($)	Sep. 30, 2015	Dec. 31, 2014
Schedule of Accrued Liabilities [Abstract]
Amounts payable to the Guarantors of the Company’s loan agreement with Bank of America and Seaside Bank, including fees and interest	$ 40,205	$ 1,533,217
Interest payable on notes payable	451,937	685,575
Vendor accruals and other	141,582	120,836
Employee commissions, compensation, etc.	22,417	33,987
	$ 656,141	$ 2,373,615

NOTE 6 - STOCK PURCHASE AGREE35

NOTE 6 - STOCK PURCHASE AGREEMENT (Details) - USD ($)	Oct. 23, 2014	Sep. 30, 2015	Dec. 31, 2014
NOTE 6 - STOCK PURCHASE AGREEMENT (Details) [Line Items]
Common Stock, Par or Stated Value Per Share		$ 0.001	$ 0.001
Stock Issued During Period, Value, New Issues		$ 582,808
Stock Purchase Agreement [Member]
NOTE 6 - STOCK PURCHASE AGREEMENT (Details) [Line Items]
Stock Repurchase Program, Authorized Amount	$ 3,000,000
Common Stock, Par or Stated Value Per Share	$ 0.001
Stock Repurchase Program, Period in Force	24 months
Purchase Commitment, Description	From time to time over the term of the Purchase Agreement, commencing on the trading day immediately following the date on which the initial registration statement was declared effective by the Securities and Exchange Commission (the “Commission”), the Company may provide the Investor with a draw down notice to purchase a specified dollar amount of Shares, with each draw down subject to certain limitations. The Company may not deliver any Draw Down Notice to the Investor if the Initial Purchase Price with respect to the Shares subject to such Draw Down Notice is less than $2.50 as of the date the applicable Draw Down Notice is received by the Investor (the “Draw Down Exercise Date”).The applicable Initial Purchase Price, the “Initial Purchase Price”, is defined as a price equal to 93% of the lowest of (i) the arithmetic average of the three lowest daily volume weighted average prices for the Company’s common stock (the “VWAP”) during the 10 consecutive trading days ending on the trading day immediately preceding the applicable Draw Down Exercise Date, (ii) the arithmetic average of the three lowest closing sale prices for the Company’s common stock during the 10 consecutive trading days ending on the trading day immediately preceding the applicable Draw Down Exercise Date and (iii) the closing sale price for the Company’s common stock on the trading day immediately preceding the applicable Draw Down Exercise Date.
Stock Issued During Period, Shares, New Issues		7,852	12,000
Stock Issued During Period, Value, New Issues		$ 61,270
Stock Purchase Agreement, Magna Equities II, LLC [Member]
NOTE 6 - STOCK PURCHASE AGREEMENT (Details) [Line Items]
Stock Issued During Period, Shares, New Issues		87,812
Stock Issued During Period, Value, New Issues		$ 521,538

NOTE 7 - NOTES PAYABLE (Details

NOTE 7 - NOTES PAYABLE (Details)	Aug. 06, 2015$ / shares	Jun. 01, 2015USD ($)	Jul. 31, 2015USD ($)	Sep. 30, 2015USD ($)$ / shares	Sep. 30, 2014USD ($)	Mar. 31, 2014	Sep. 30, 2015USD ($)$ / shares	Sep. 30, 2014USD ($)	Dec. 31, 2014USD ($)	Oct. 25, 2010USD ($)
NOTE 7 - NOTES PAYABLE (Details) [Line Items]
Notes Payable				$ 1,815,532			$ 1,815,532		$ 1,870,972
Derivative Liability, Current				399,328			399,328		741,271
Debt Instrument, Unamortized Discount				180,032			180,032		339,160
Gains (Losses) on Extinguishment of Debt				58,873	$ 85,229		2,097,483	$ 2,272,283
Amortization of Debt Discount (Premium)							612,811	$ 343,592
Notes Payable, Other Payables [Member]
NOTE 7 - NOTES PAYABLE (Details) [Line Items]
Debt Instrument, Unamortized Discount				259,720			259,720
Convertible Debt [Member] | Embedded Derivative Financial Instruments [Member]
NOTE 7 - NOTES PAYABLE (Details) [Line Items]
Embedded Derivative, Fair Value of Embedded Derivative Liability				64,595			64,595
Debt Conversion, Original Debt, Amount							140,405
Seaside National Bank and Trust [Member] | Notes Payable to Banks [Member]
NOTE 7 - NOTES PAYABLE (Details) [Line Items]
Debt Instrument, Face Amount										$ 980,000
Debt Instrument, Interest Rate, Stated Percentage										4.25%
Debt Instrument, Maturity Date						Dec. 23, 2015
Notes Payable				$ 980,000			$ 980,000		$ 980,000
Hunton & Williams Notes [Member] | Notes Payable, Other Payables [Member]
NOTE 7 - NOTES PAYABLE (Details) [Line Items]
Debt Instrument, Interest Rate, Stated Percentage				8.00%			8.00%		8.00%
Number of Outstanding Notes Payable				2			2		2
Notes Payable				$ 384,972			$ 384,972		$ 384,972
Debt Instrument, Payment Terms							payable in one balloon payment upon the date the Noteholder provides written demand, however the Company is not obligated to make payments until the Northstar (or successor) Loan is paid off.		payable in one balloon payment upon the date the Noteholder provides written demand, however the Company is not obligated to make payments until the Northstar (or successor) Loan is paid off.
Hunton & Williams Note #1 [Member] | Notes Payable, Other Payables [Member]
NOTE 7 - NOTES PAYABLE (Details) [Line Items]
Notes Payable				61,150			$ 61,150		$ 61,150
Hunton & Williams Note #2 [Member] | Notes Payable, Other Payables [Member]
NOTE 7 - NOTES PAYABLE (Details) [Line Items]
Notes Payable				323,822			323,822		323,822
Asher Notes Payable [Member] | Convertible Debt [Member]
NOTE 7 - NOTES PAYABLE (Details) [Line Items]
Debt Instrument, Face Amount				$ 180,000			$ 180,000
Debt Instrument, Interest Rate, Stated Percentage				8.00%			8.00%
Debt Instrument, Maturity Date							Feb. 6, 2016
Notes Payable				$ 66,000			$ 66,000		151,000
Legal Fees							$ 15,000
Debt Instrument, Term							9 years
Debt Instrument, Convertible, Terms of Conversion Feature							convertible into shares of common stock, at Asher’s option, at a 45% discount to the average of the three lowest closing bid prices of the shares of common stock during the 10 trading day period prior to conversion.
Asher Notes Payable [Member] | Convertible Debt [Member] | Conversion of Debt, Notes and Accrued Interest #1 [Member]
NOTE 7 - NOTES PAYABLE (Details) [Line Items]
Debt Conversion, Original Debt, Amount							$ 151,000
Asher Notes Payable [Member] | Convertible Debt [Member] | Conversion of Debt, Notes and Accrued Interest #2 [Member]
NOTE 7 - NOTES PAYABLE (Details) [Line Items]
Debt Conversion, Original Debt, Amount							114,000
Asher Notes Payable [Member] | Convertible Debt [Member] | Embedded Derivative Financial Instruments [Member]
NOTE 7 - NOTES PAYABLE (Details) [Line Items]
Derivative Liability, Current				72,522			72,522
Embedded Derivative, Fair Value of Embedded Derivative Liability				211,575			211,575
Daniel James Management Notes Payable [Member] | Convertible Debt [Member]
NOTE 7 - NOTES PAYABLE (Details) [Line Items]
Debt Instrument, Face Amount				$ 100,000			$ 100,000
Debt Instrument, Interest Rate, Stated Percentage				9.50%			9.50%
Debt Instrument, Maturity Date							Sep. 1, 2016
Notes Payable				$ 75,000			$ 75,000		75,000
Debt Instrument, Term							1 year
Debt Instrument, Convertible, Terms of Conversion Feature							convertible into common stock, at holder’s option, at a 47% discount to the average of the three lowest closing bid prices of the common stock during the 10 trading day period prior to conversion
Daniel James Management Notes Payable [Member] | Convertible Debt [Member] | Conversion of Debt, Notes and Accrued Interest #1 [Member]
NOTE 7 - NOTES PAYABLE (Details) [Line Items]
Debt Conversion, Original Debt, Amount							$ 75,000
Daniel James Management Notes Payable [Member] | Convertible Debt [Member] | Conversion of Debt, Notes and Accrued Interest #2 [Member]
NOTE 7 - NOTES PAYABLE (Details) [Line Items]
Debt Conversion, Original Debt, Amount							25,000
Daniel James Management Notes Payable [Member] | Convertible Debt [Member] | Embedded Derivative Financial Instruments [Member]
NOTE 7 - NOTES PAYABLE (Details) [Line Items]
Derivative Liability, Current				110,537			110,537
Embedded Derivative, Fair Value of Embedded Derivative Liability				180,930			180,930
Fourth Man, LLC Notes Payable [Member] | Convertible Debt [Member]
NOTE 7 - NOTES PAYABLE (Details) [Line Items]
Debt Instrument, Face Amount				100,000			$ 100,000
Debt Instrument, Maturity Date							Jul. 31, 2016
Notes Payable				75,000			$ 75,000		75,000
Debt Instrument, Term							1 year
Debt Instrument, Convertible, Terms of Conversion Feature							convertible into shares of common stock, at Fourth Man’s option, at a 47% discount to the lowest closing bid price of the common stock during the 10 trading day period prior to conversion
Fourth Man, LLC Notes Payable [Member] | Convertible Debt [Member] | Conversion of Debt, Notes and Accrued Interest #1 [Member]
NOTE 7 - NOTES PAYABLE (Details) [Line Items]
Debt Conversion, Original Debt, Amount							$ 75,000
Fourth Man, LLC Notes Payable [Member] | Convertible Debt [Member] | Conversion of Debt, Notes and Accrued Interest #2 [Member]
NOTE 7 - NOTES PAYABLE (Details) [Line Items]
Debt Conversion, Original Debt, Amount							25,000
Fourth Man, LLC Notes Payable [Member] | Convertible Debt [Member] | Embedded Derivative Financial Instruments [Member]
NOTE 7 - NOTES PAYABLE (Details) [Line Items]
Derivative Liability, Current				108,731			108,731
Embedded Derivative, Fair Value of Embedded Derivative Liability				198,855			198,855
Magna Group Notes Payable [Member] | Convertible Debt [Member]
NOTE 7 - NOTES PAYABLE (Details) [Line Items]
Debt Instrument, Maturity Date	Nov. 7, 2015
Notes Payable				64,595			64,595		205,000
Debt Instrument, Convertible, Terms of Conversion Feature	lesser of a) $0.006 or b) a 40% discount from the lowest trading price in the five trading days prior to conversion
Debt Instrument, Convertible, Conversion Price (in Dollars per share) | $ / shares	$ 0.01035
Magna Group Notes Payable [Member] | Convertible Debt [Member] | Embedded Derivative Financial Instruments [Member]
NOTE 7 - NOTES PAYABLE (Details) [Line Items]
Derivative Liability, Current				83,787			83,787
Power Up Lending Group Notes Payable [Member] | Notes Payable, Other Payables [Member]
NOTE 7 - NOTES PAYABLE (Details) [Line Items]
Notes Payable				169,965			169,965		0
Power Up Lending Group Notes Payable [Member] | Convertible Debt [Member]
NOTE 7 - NOTES PAYABLE (Details) [Line Items]
Debt Instrument, Face Amount			$ 243,000
Debt Instrument, Payment Terms			Under the terms of the agreements, the Company is required to make daily payments equal to the greater of $1,464 or 20% of the Company’s daily cash or monetary sales receipts over the term of the agreements (ranging from 126 to 189 business days).
Proceeds from Convertible Debt			$ 180,000
Debt Instrument, Fee Amount			3,590
Interest Expense, Debt							20,014
Debt Instrument, Unamortized Discount				46,576			46,576
Former Officers and Directors, Non-Related Notes Payable [Member] | Notes Payable, Other Payables [Member]
NOTE 7 - NOTES PAYABLE (Details) [Line Items]
Debt Instrument, Face Amount									$ 1,500,000
Note Payable, Settlement of Subordinated Debt, Accrued Interest and Guarantor Fees [Member] | Notes Payable, Other Payables [Member]
NOTE 7 - NOTES PAYABLE (Details) [Line Items]
Debt Instrument, Face Amount		$ 1,697,762
Debt Instrument, Interest Rate, Stated Percentage		0.00%
Debt Instrument, Maturity Date		Jun. 1, 2020
Debt Instrument, Term		5 years
Debt Instrument, Unamortized Discount			$ 368,615
Debt Instrument, Frequency of Periodic Payment		four semi-annual
Debt Instrument, Periodic Payment		$ 75,000
Debt Instrument, Date of First Required Payment		Dec. 31, 2015
Debt Instrument, Imputed Interest, Stated Percentage			5.00%
Gains (Losses) on Extinguishment of Debt		$ 1,169,058
Amortization of Debt Discount (Premium)				21,396			28,141
Note Payable, Settlement of Subordinated Debt, Accrued Interest and Guarantor Fees [Member] | Notes Payable, Other Payables [Member] | Principal [Member]
NOTE 7 - NOTES PAYABLE (Details) [Line Items]
Extinguishment of Debt, Amount		1,500,000
Note Payable, Settlement of Subordinated Debt, Accrued Interest and Guarantor Fees [Member] | Notes Payable, Other Payables [Member] | Interest [Member]
NOTE 7 - NOTES PAYABLE (Details) [Line Items]
Extinguishment of Debt, Amount		373,469
Note Payable, Settlement of Subordinated Debt, Accrued Interest and Guarantor Fees [Member] | Notes Payable, Other Payables [Member] | Guarantor Fees [Member]
NOTE 7 - NOTES PAYABLE (Details) [Line Items]
Extinguishment of Debt, Amount		$ 624,737
Asher, Daniel, Fourth Man LLC and Magna Notes [Member] | Convertible Debt [Member] | Embedded Derivative Financial Instruments [Member]
NOTE 7 - NOTES PAYABLE (Details) [Line Items]
Embedded Derivative, Fair Value of Embedded Derivative Liability				375,577			375,577
Proceeds from Convertible Debt							363,964
Interest Expense, Debt							227,396
Debt Instrument, Unamortized Discount				591,360			591,360
Amortization of Debt Discount (Premium)				$ 207,196			$ 632,825
Fair Value Assumptions, Expected Dividend Rate							0.00%
Minimum [Member] | Fourth Man, LLC Notes Payable [Member] | Convertible Debt [Member]
NOTE 7 - NOTES PAYABLE (Details) [Line Items]
Debt Instrument, Interest Rate, Stated Percentage				8.00%			8.00%
Minimum [Member] | Power Up Lending Group Notes Payable [Member] | Convertible Debt [Member]
NOTE 7 - NOTES PAYABLE (Details) [Line Items]
Debt Instrument, Term			126 days
Minimum [Member] | Former Officers and Directors, Non-Related Notes Payable [Member] | Notes Payable, Other Payables [Member]
NOTE 7 - NOTES PAYABLE (Details) [Line Items]
Debt Instrument, Interest Rate, Stated Percentage									4.75%
Minimum [Member] | Asher, Daniel, Fourth Man LLC and Magna Notes [Member] | Convertible Debt [Member] | Embedded Derivative Financial Instruments [Member]
NOTE 7 - NOTES PAYABLE (Details) [Line Items]
Fair Value Assumptions, Expected Volatility Rate							111.98%
Fair Value Assumptions, Risk Free Interest Rate							0.17%
Fair Value Assumptions, Expected Term							9 months
Share Price (in Dollars per share) | $ / shares				$ 0.0019			$ 0.0019
Maximum [Member] | Fourth Man, LLC Notes Payable [Member] | Convertible Debt [Member]
NOTE 7 - NOTES PAYABLE (Details) [Line Items]
Debt Instrument, Interest Rate, Stated Percentage				9.50%			9.50%
Maximum [Member] | Power Up Lending Group Notes Payable [Member] | Convertible Debt [Member]
NOTE 7 - NOTES PAYABLE (Details) [Line Items]
Debt Instrument, Term			189 days
Maximum [Member] | Former Officers and Directors, Non-Related Notes Payable [Member] | Notes Payable, Other Payables [Member]
NOTE 7 - NOTES PAYABLE (Details) [Line Items]
Debt Instrument, Interest Rate, Stated Percentage									8.00%
Maximum [Member] | Asher, Daniel, Fourth Man LLC and Magna Notes [Member] | Convertible Debt [Member] | Embedded Derivative Financial Instruments [Member]
NOTE 7 - NOTES PAYABLE (Details) [Line Items]
Fair Value Assumptions, Expected Volatility Rate							147.97%
Fair Value Assumptions, Risk Free Interest Rate							0.37%
Fair Value Assumptions, Expected Term							1 year
Share Price (in Dollars per share) | $ / shares				$ 0.0127			$ 0.0127

NOTE 7 - NOTES PAYABLE (Detai37

NOTE 7 - NOTES PAYABLE (Details) - Schedule of Notes Payable - USD ($)	Sep. 30, 2015	Dec. 31, 2014
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Notes Payable [Line Items]
Notes Payable, Gross	$ 1,815,532	$ 1,870,972
Less unamortized debt discount	(180,032)	(339,160)
Total notes payable net of unamortized debt discount	1,635,500	1,531,812
Notes Payable, Other Payables [Member]
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Notes Payable [Line Items]
Less unamortized debt discount	(259,720)
Seaside National Bank and Trust [Member] | Notes Payable to Banks [Member]
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Notes Payable [Line Items]
Notes Payable, Gross	980,000	980,000
Hunton & Williams Notes [Member] | Notes Payable, Other Payables [Member]
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Notes Payable [Line Items]
Notes Payable, Gross	384,972	384,972
Asher Notes Payable [Member] | Convertible Debt [Member]
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Notes Payable [Line Items]
Notes Payable, Gross	66,000	151,000
Daniel James Management Notes Payable [Member] | Convertible Debt [Member]
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Notes Payable [Line Items]
Notes Payable, Gross	75,000	75,000
Fourth Man, LLC Notes Payable [Member] | Convertible Debt [Member]
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Notes Payable [Line Items]
Notes Payable, Gross	75,000	75,000
Magna Group Notes Payable [Member] | Convertible Debt [Member]
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Notes Payable [Line Items]
Notes Payable, Gross	64,595	205,000
Power Up Lending Group Notes Payable [Member] | Notes Payable, Other Payables [Member]
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Notes Payable [Line Items]
Notes Payable, Gross	169,965	$ 0
Power Up Lending Group Notes Payable [Member] | Convertible Debt [Member]
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Notes Payable [Line Items]
Less unamortized debt discount	$ (46,576)

NOTE 8 - RELATED PARTY TRANSA38

NOTE 8 - RELATED PARTY TRANSACTIONS (Details) - USD ($)	Apr. 03, 2015	Oct. 03, 2014	Jul. 01, 2014	Apr. 02, 2014	Dec. 24, 2013	Sep. 30, 2013	Oct. 01, 2012	Sep. 21, 2012	Mar. 30, 2012	Sep. 30, 2015	Sep. 30, 2015	Dec. 31, 2014	Dec. 31, 2013	Aug. 01, 2013	Feb. 28, 2013	Feb. 29, 2012
NOTE 8 - RELATED PARTY TRANSACTIONS (Details) [Line Items]
Due to Related Parties, Current										$ 155,363	$ 155,363	$ 148,759
Class of Warrant or Rights, Granted (in Shares)											1,444	57,582
Preferred Stock, Shares Authorized (in Shares)										20,000,000	20,000,000	20,000,000
Notes Payable, Related Parties										$ 1,880,262	$ 1,880,262	$ 1,971,059
Series A Preferred Stock [Member]
NOTE 8 - RELATED PARTY TRANSACTIONS (Details) [Line Items]
Preferred Stock, Voting Rights							modify the voting rights of the Series A Convertible Preferred Stock from 20 votes per share on matters to be voted on by the common stock holders to 25 votes per share on matters to be voted on by the common stock holders and all prior and subsequent payments of interest will be in common stock
Immediate Family Member of Management or Principal Owner [Member]
NOTE 8 - RELATED PARTY TRANSACTIONS (Details) [Line Items]
Related Party Transaction, Purchases from Related Party										69,973	242,271
Notes Payable, Other Payables [Member] | Affiliated Entity [Member]
NOTE 8 - RELATED PARTY TRANSACTIONS (Details) [Line Items]
Debt Instrument, Face Amount																$ 544,267
Debt Instrument, Payment Terms							Company is obligated to issue additional preferred stock equal in lieu of payment of cash of accrued and unpaid interest on each six month anniversary of the effective date (October 1, 2012).		agreed to extend until May 1, 2012 the initial payment date for any and all required monthly under the Note, such that the first of the four monthly payments required under the Note will be due and payable on May, 2012 and all subsequent payments will be due on a monthly basis thereafter commencing on June 1, 2012, and to waive any and all defaults and/or events of default under the Note with respect to such payments. The Company did not make the required payment, and as a result, was in default of the revised agreement The Company renegotiated the terms of the Note and Northstar agreed to suspend the requirement of principal payments by the Company and allow payment of interest-only in common stock.
Class of Warrant or Rights, Granted (in Shares)							15,000	5,000
Debt Instrument, Debt Default, Description of Violation or Event of Default							entered into a limited waiver and forbearance agreement providing a recapitalized new note balance comprised of all sums due Northstar with a maturity date extended perpetually. The Company agreed to issue 5,000,000 shares of Series A Convertible Preferred Stock and 10,000 of common stock in exchange for $210,000 as payment towards outstanding debt, default interest, penalties, professional fees outstanding and due Northstar. In addition, the Company executed a security agreement granting Northstar a lien on all patents, patent applications, trademarks, service marks, copyrights and intellectual property rights of any nature, as well as the results of all clinical trials, know-how for preparing Myoblasts, old and new clinical data, existing approved trials, all right and title to Myoblasts, clinical trial protocols and other property rights.In addition, the Company granted Northstar a perpetual license on products as described for resale, relicensing and commercialization outside the United States. In connection with the granted license, Northstar shall pay the Company a royalty of up to 8% on revenues generated.
PercentageOfRevenuesToBeReceivedAsRoyalty							8.00%
Debt Instrument, Interest Rate, Stated Percentage							12.85%								7.00%
Debt Conversion, Converted Instrument, Shares Issued (in Shares)					3,916	8,772							10,000
Debt Conversion, Converted Instrument, Amount					$ 85,447	$ 100,000							$ 210,000
Notes Payable, Related Parties										$ 362,000	$ 362,000	$ 362,000
Notes Payable, Other Payables [Member] | Affiliated Entity [Member] | Series A Preferred Stock [Member]
NOTE 8 - RELATED PARTY TRANSACTIONS (Details) [Line Items]
Debt Conversion, Converted Instrument, Shares Issued (in Shares)													5,000,000
Stock Issued During Period, Value, Other													$ 274,050
Notes Payable, Other Payables [Member] | Affiliated Entity [Member] | Series A Preferred Stock [Member] | Settlement of Forbearance Agreement, Penalty [Member]
NOTE 8 - RELATED PARTY TRANSACTIONS (Details) [Line Items]
Stock Issued During Period, Shares, Other (in Shares)													15,000,000
Notes Payable, Other Payables [Member] | Director [Member]
NOTE 8 - RELATED PARTY TRANSACTIONS (Details) [Line Items]
Debt Instrument, Payment Terms											The Company is not obligated to make payment until Northstar (or successor) Loan is paid off.
Debt Instrument, Interest Rate, Stated Percentage										8.00%	8.00%	8.00%
Notes Payable, Related Parties										$ 465,240	$ 465,240	$ 465,240
Notes Payable, Other Payables [Member] | Chief Scientific Officer [Member]
NOTE 8 - RELATED PARTY TRANSACTIONS (Details) [Line Items]
Debt Instrument, Face Amount			$ 300,000
Debt Instrument, Interest Rate, Stated Percentage			5.00%
Notes Payable, Related Parties										$ 287,772	287,772	299,465
Debt Instrument, Maturity Date			Jan. 1, 2015
Repayments of Related Party Debt											$ 11,693
Notes Payable, Other Payables [Member] | Interest [Member] | Affiliated Entity [Member]
NOTE 8 - RELATED PARTY TRANSACTIONS (Details) [Line Items]
Debt Conversion, Converted Instrument, Shares Issued (in Shares)	1,363	515		275							1,363
Debt Conversion, Converted Instrument, Amount	$ 12,635	$ 12,705		$ 12,635
Note Payable #1 [Member] | Notes Payable, Other Payables [Member] | Chief Executive Officer [Member]
NOTE 8 - RELATED PARTY TRANSACTIONS (Details) [Line Items]
Debt Instrument, Interest Rate, Stated Percentage										5.00%	5.00%
Notes Payable, Related Parties										$ 252,250	$ 252,250	331,354
Repayments of Related Party Debt											79,104
Note Payable #1 [Member] | Subordinated Debt [Member] | Director [Member]
NOTE 8 - RELATED PARTY TRANSACTIONS (Details) [Line Items]
Notes Payable, Related Parties										100,000	$ 100,000
Debt Instrument, Maturity Date											Nov. 30, 2012
Note Payable #2 [Member] | Notes Payable, Other Payables [Member] | Chief Executive Officer [Member]
NOTE 8 - RELATED PARTY TRANSACTIONS (Details) [Line Items]
Debt Instrument, Face Amount														$ 375,000
Debt Instrument, Interest Rate, Stated Percentage														5.00%
Notes Payable, Related Parties										375,000	$ 375,000	375,000
Note Payable #2 [Member] | Subordinated Debt [Member] | Director [Member]
NOTE 8 - RELATED PARTY TRANSACTIONS (Details) [Line Items]
Notes Payable, Related Parties										140,000	$ 140,000
Debt Instrument, Maturity Date											Jun. 4, 2011
Note Payable #3 [Member] | Notes Payable, Other Payables [Member] | Chief Executive Officer [Member]
NOTE 8 - RELATED PARTY TRANSACTIONS (Details) [Line Items]
Debt Instrument, Face Amount			$ 500,000
Debt Instrument, Interest Rate, Stated Percentage			5.00%
Notes Payable, Related Parties										$ 500,000	$ 500,000	$ 500,000
Debt Instrument, Maturity Date			Jan. 1, 2015

NOTE 8 - RELATED PARTY TRANSA39

NOTE 8 - RELATED PARTY TRANSACTIONS (Details) - Schedule of Related Party Notes Payable - USD ($)	Sep. 30, 2015	Dec. 31, 2014
Related Party Transaction [Line Items]
Notes Payable, Related Party	$ 1,880,262	$ 1,971,059
Director [Member] | Notes Payable, Other Payables [Member]
Related Party Transaction [Line Items]
Notes Payable, Related Party	465,240	465,240
Chief Executive Officer [Member] | Note Payable #1 [Member] | Notes Payable, Other Payables [Member]
Related Party Transaction [Line Items]
Notes Payable, Related Party	252,250	331,354
Chief Executive Officer [Member] | Note Payable #2 [Member] | Notes Payable, Other Payables [Member]
Related Party Transaction [Line Items]
Notes Payable, Related Party	375,000	375,000
Chief Executive Officer [Member] | Note Payable #3 [Member] | Notes Payable, Other Payables [Member]
Related Party Transaction [Line Items]
Notes Payable, Related Party	500,000	500,000
Chief Scientific Officer [Member] | Notes Payable, Other Payables [Member]
Related Party Transaction [Line Items]
Notes Payable, Related Party	$ 287,772	$ 299,465

NOTE 9 - DERIVATIVE LIABILITI40

NOTE 9 - DERIVATIVE LIABILITIES (Details) - USD ($)	Oct. 01, 2012	Sep. 21, 2012	Sep. 30, 2015	Sep. 30, 2015	Dec. 31, 2014	Dec. 31, 2012
NOTE 9 - DERIVATIVE LIABILITIES (Details) [Line Items]
Class of Warrant or Rights, Granted (in Shares)				1,444	57,582
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)			$ 182.90	$ 182.90	$ 10	$ 220
Warrant [Member] | Embedded Derivative Financial Instruments [Member]
NOTE 9 - DERIVATIVE LIABILITIES (Details) [Line Items]
Embedded Derivative, Fair Value of Embedded Derivative, Net (in Dollars)			$ 23,751	$ 23,751
Fair Value Assumptions, Expected Dividend Rate				0.00%
Fair Value Assumptions, Expected Volatility Rate				136.32%
Fair Value Assumptions, Risk Free Interest Rate				1.74%
Fair Value Assumptions, Expected Term				7 years
Derivative, Gain (Loss) on Derivative, Net (in Dollars)			58,760	$ 126,168
Debt [Member] | Embedded Derivative Financial Instruments [Member]
NOTE 9 - DERIVATIVE LIABILITIES (Details) [Line Items]
Embedded Derivative, Fair Value of Embedded Derivative, Net (in Dollars)			375,577	$ 375,577
Fair Value Assumptions, Expected Dividend Rate				0.00%
Fair Value Assumptions, Expected Volatility Rate				136.32%
Derivative, Gain (Loss) on Derivative, Net (in Dollars)			$ 315,924	$ 134,784
Fair Value of Common Stock (in Dollars per share)				$ 0.0019
Affiliated Entity [Member] | Notes Payable, Other Payables [Member]
NOTE 9 - DERIVATIVE LIABILITIES (Details) [Line Items]
Class of Warrant or Rights, Granted (in Shares)	15,000	5,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)	$ 0.014
Warrants, Term of Warrants	10 years
Minimum [Member] | Debt [Member] | Embedded Derivative Financial Instruments [Member]
NOTE 9 - DERIVATIVE LIABILITIES (Details) [Line Items]
Fair Value Assumptions, Risk Free Interest Rate				0.01%
Fair Value Assumptions, Expected Term				3 months
Maximum [Member] | Debt [Member] | Embedded Derivative Financial Instruments [Member]
NOTE 9 - DERIVATIVE LIABILITIES (Details) [Line Items]
Fair Value Assumptions, Risk Free Interest Rate				0.33%
Fair Value Assumptions, Expected Term				335 days

NOTE 10 - STOCKHOLDERS' EQUITY

NOTE 10 - STOCKHOLDERS' EQUITY (Details) - USD ($)

Oct. 12, 2015

Apr. 03, 2015

Mar. 19, 2015

Oct. 03, 2014

Apr. 02, 2014

Dec. 24, 2013

Sep. 30, 2013

Oct. 01, 2012

Sep. 21, 2012

Sep. 30, 2015

Sep. 30, 2014

Sep. 30, 2015

Sep. 30, 2014

Dec. 31, 2014

Dec. 31, 2013

Oct. 23, 2014

NOTE 10 - STOCKHOLDERS' EQUITY (Details) [Line Items]

Common Stock, Par or Stated Value Per Share (in Dollars per share)

$ 0.001

$ 0.001

$ 0.001

Adjustments to Additional Paid in Capital, Stock Split

$ 580,852

Gains (Losses) on Extinguishment of Debt

$ 58,873

$ 85,229

$ 2,097,483

$ 2,272,283

Stock Issued During Period, Shares, Settlement of Litigation (in Shares)

6,650

6,650

Gain (Loss) Related to Litigation Settlement

$ (59,850)

$ 0

Stock Issued During Period, Value, New Issues

$ 582,808

Class of Warrant or Rights, Granted (in Shares)

1,444

57,582

Stock Purchase Agreement, Magna Equities II, LLC [Member]

NOTE 10 - STOCKHOLDERS' EQUITY (Details) [Line Items]

Stock Issued During Period, Shares, New Issues (in Shares)

87,812

Stock Issued During Period, Value, New Issues

$ 521,538

Stock Purchase Agreement [Member]

NOTE 10 - STOCKHOLDERS' EQUITY (Details) [Line Items]

Common Stock, Par or Stated Value Per Share (in Dollars per share)

$ 0.001

Stock Issued During Period, Shares, New Issues (in Shares)

7,852

12,000

Stock Issued During Period, Value, New Issues

$ 61,270

Class of Warrant or Rights, Granted (in Shares)

1,443,656

Subsequent Event [Member]

NOTE 10 - STOCKHOLDERS' EQUITY (Details) [Line Items]

Stockholders' Equity, Reverse Stock Split

1-for-1,000

Common Stock [Member]

NOTE 10 - STOCKHOLDERS' EQUITY (Details) [Line Items]

Stock Issued During Period, Shares, Settlement of Litigation (in Shares)

6,650

Stock Repurchased During Period, Shares (in Shares)

37,852

Treasury Stock Acquired, Average Cost Per Share (in Dollars per share)

$ 4.17

Stock Issued During Period, Shares, New Issues (in Shares)

95,664

Stock Issued During Period, Value, New Issues

$ 96

Common Stock Issued in Settlement of Accounts Payable, Accrued Expenses and Accrued Interest [Member]

NOTE 10 - STOCKHOLDERS' EQUITY (Details) [Line Items]

Debt Conversion, Converted Instrument, Shares Issued (in Shares)

20,819

Debt Conversion, Original Debt, Amount

$ 152,777

Gains (Losses) on Extinguishment of Debt

$ 86,763

Common Stock Issued in Settlement of Notes Payable and Accrued Interest [Member]

NOTE 10 - STOCKHOLDERS' EQUITY (Details) [Line Items]

Debt Conversion, Converted Instrument, Shares Issued (in Shares)

247,524

Debt Conversion, Original Debt, Amount

$ 623,237

Common Stock Issued in Settlement of Guarantor Fees [Member]

NOTE 10 - STOCKHOLDERS' EQUITY (Details) [Line Items]

Debt Conversion, Converted Instrument, Shares Issued (in Shares)

24,353

Debt Conversion, Original Debt, Amount

$ 961,125

Gains (Losses) on Extinguishment of Debt

$ 791,024

Notes Payable, Other Payables [Member] | Affiliated Entity [Member]

NOTE 10 - STOCKHOLDERS' EQUITY (Details) [Line Items]

Debt Conversion, Converted Instrument, Shares Issued (in Shares)

3,916

8,772

10,000

Class of Warrant or Rights, Granted (in Shares)

15,000

5,000

Notes Payable, Other Payables [Member] | Interest [Member] | Affiliated Entity [Member]

NOTE 10 - STOCKHOLDERS' EQUITY (Details) [Line Items]

Debt Conversion, Converted Instrument, Shares Issued (in Shares)

1,363

515

275

1,363

Debt Conversion, Original Debt, Amount

$ 12,635

Fair Value, Inputs, Level 3 [Member] | Embedded Derivative Financial Instruments [Member] | Debt [Member]

NOTE 10 - STOCKHOLDERS' EQUITY (Details) [Line Items]

Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Transfers out of Level 3

$ (672,350)

$ (680,295)

NOTE 11 - STOCK OPTIONS AND W42

NOTE 11 - STOCK OPTIONS AND WARRANTS (Details) - USD ($)	Aug. 24, 2015	Feb. 02, 2015	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014	Nov. 02, 2015	Aug. 04, 2014	Apr. 01, 2013	Dec. 31, 2012
NOTE 11 - STOCK OPTIONS AND WARRANTS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross					7,100		43,148
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price					$ 11.16		$ 23
Share-based Compensation					$ 341,629	$ 446,366
Class of Warrant or Rights, Granted					1,444		57,582
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 182.90		$ 182.90		$ 10				$ 220
Bioheart 2013 Omnibus Equity Compensation Plan [Member]
NOTE 11 - STOCK OPTIONS AND WARRANTS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized									100,000	50,000
Bioheart 2013 Omnibus Equity Compensation Plan [Member] | Options Issued to Consultant [Member]
NOTE 11 - STOCK OPTIONS AND WARRANTS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	100
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price	$ 5.31
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights	vesting immediately
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period	4 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value	$ 347
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate	0.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate	129.01%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate	1.39%
Subsequent Event [Member] | Bioheart 2013 Omnibus Equity Compensation Plan [Member]
NOTE 11 - STOCK OPTIONS AND WARRANTS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized								500,000,000
Director [Member] | Bioheart 2013 Omnibus Equity Compensation Plan [Member]
NOTE 11 - STOCK OPTIONS AND WARRANTS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross		7,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price		$ 11.16
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights		vesting immediately
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period		10 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value		$ 121,735
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate		0.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate		142.65%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate		1.68%
Share-based Compensation			$ 73,520	$ 164,247	$ 345,761	$ 407,616
Affiliated Entity [Member] | Convertible Debt [Member]
NOTE 11 - STOCK OPTIONS AND WARRANTS (Details) [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 11.27		$ 11.27
Warrants, Term of Warrants					10 years

NOTE 11 - STOCK OPTIONS AND W43

NOTE 11 - STOCK OPTIONS AND WARRANTS (Details) - Schedule of Option Activity - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2014	Dec. 31, 2013
Schedule of Option Activity [Abstract]
Options Outstanding	66,933		23,921
Options Outstanding, Weighted-Average Exercise Price (in Dollars per share)	$ 56		$ 150
Options Outstanding, Weighted-Average Remaining Contractual Term	8 years 109 days	8 years 328 days	9 years
Options exercisable at September 30, 2015	44,468
Options exercisable at September 30, 2015 (in Dollars per share)	$ 46.41
Options exercisable at September 30, 2015	8 years 109 days
Available for grant at September 30, 2015	89,400
Options Granted	7,100	43,148
Options Granted, Weighted-Average Exercise Price (in Dollars per share)	$ 11.16	$ 23
Options Granted, Weighted-Average Remaining Contractual Term	10 years	10 years
Options Exercised	0	0
Options Forfeited/Expired	(229)	(136)
Options Forfeited/Expired, Weighted-Average Exercise Price (in Dollars per share)	$ 5,112.48	$ 5,200
Options Outstanding	73,804	66,933
Options Outstanding, Weighted-Average Exercise Price (in Dollars per share)	$ 36.32	$ 56

NOTE 11 - STOCK OPTIONS AND W44

NOTE 11 - STOCK OPTIONS AND WARRANTS (Details) - Schedule of Options Outstanding and Exercisable by Exercise Price Range	9 Months Ended
	Sep. 30, 2015$ / sharesshares
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding | shares	73,804
Options Outstanding, Weighted-Average Exercise Price	$ 36.32
Options Exercisable | shares	44,468
Options Outstanding, Weighted-Average Remaining Contractual Term	8 years 109 days
Options Exercisable, Weighted-Average Exercise Price	$ 46.41
Options, Exercise Price Range, $0.00-$20.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding | shares	52,690
Options Outstanding, Weighted-Average Exercise Price	$ 16.73
Options Exercisable | shares	34,490
Options Outstanding, Weighted-Average Remaining Contractual Term	8 years 73 days
Options Exercisable, Weighted-Average Exercise Price	$ 16.38
Options, Exercise Price Range, $20.01-$30.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding | shares	19,849
Options Outstanding, Weighted-Average Exercise Price	$ 26.96
Options Exercisable | shares	8,713
Options Outstanding, Weighted-Average Remaining Contractual Term	8 years 292 days
Options Exercisable, Weighted-Average Exercise Price	$ 26.94
Options, Exercise Price Range, $30.01-$100.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding | shares	300
Options Outstanding, Weighted-Average Exercise Price	$ 70
Options Exercisable | shares	300
Options Outstanding, Weighted-Average Remaining Contractual Term	5 years 328 days
Options Exercisable, Weighted-Average Exercise Price	$ 70
Options, Exercise Price Range, $100.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding | shares	965
Options Outstanding, Weighted-Average Exercise Price	$ 1,243.27
Options Exercisable | shares	965
Options Outstanding, Weighted-Average Remaining Contractual Term	4 years 109 days
Options Exercisable, Weighted-Average Exercise Price	$ 1,243.27

NOTE 11 - STOCK OPTIONS AND W45

NOTE 11 - STOCK OPTIONS AND WARRANTS (Details) - Schedule of Warrants Activity - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2014	Dec. 31, 2013
Schedule of Warrants Activity [Abstract]
Warrants Outstanding	150,620		118,134
Warrants Outstanding, Weighted-Average Exercise Price	$ 10		$ 220
Warrants Outstanding, Weighted-Average Remaining Contractual Term	6 years 6 months	6 years 219 days	6 years 109 days
Exercisable at September 30, 2015	133,194
Exercisable at September 30, 2015	$ 100.27
Exercisable at September 30, 2015	6 years 219 days
Warrants Issued	1,444	57,582
Warrants Issued, Weighted-Average Exercise Price	$ 11.27	$ 20
Warrants Issued, Weighted-Average Remaining Contractual Term	10 years	8 years 73 days
Warrants Exercised	0	(11,918)
Warrants Exercised, Weighted-Average Exercise Price	$ 0	$ 10
Warrants Expired	(13,325)	(13,178)
Warrants Expired, Weighted-Average Exercise Price	$ 24	$ 80
Warrants Outstanding	138,739	150,620
Warrants Outstanding, Weighted-Average Exercise Price	$ 182.90	$ 10

NOTE 11 - STOCK OPTIONS AND W46

NOTE 11 - STOCK OPTIONS AND WARRANTS (Details) - Schedule of Warrants Outstanding and Exercisable by Exercise Price Range - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
NOTE 11 - STOCK OPTIONS AND WARRANTS (Details) - Schedule of Warrants Outstanding and Exercisable by Exercise Price Range [Line Items]
Warrants Outstanding	138,739	150,620		118,134
Warrants Outstanding, Weighted-Average Remaining Contractual Term	6 years 6 months	6 years 219 days	6 years 109 days
Warrants Outstanding, Weighted-Average Exercise Price	$ 182.90	$ 10		$ 220
Warrants Exercisable	133,194
Warrants Exercisable, Weighted-Average Exercise Price	$ 100.27
Class of Warrants or Rights, Exercise Price Range, $0.01-$20.00 [Member]
NOTE 11 - STOCK OPTIONS AND WARRANTS (Details) - Schedule of Warrants Outstanding and Exercisable by Exercise Price Range [Line Items]
Warrants Outstanding	94,108
Warrants Outstanding, Weighted-Average Remaining Contractual Term	7 years
Warrants Outstanding, Weighted-Average Exercise Price	$ 15.54
Warrants Exercisable	94,108
Warrants Exercisable, Weighted-Average Exercise Price	$ 15.54
Class of Warrants or Rights, Exercise Price Range, $20.01-$30.00 [Member]
NOTE 11 - STOCK OPTIONS AND WARRANTS (Details) - Schedule of Warrants Outstanding and Exercisable by Exercise Price Range [Line Items]
Warrants Outstanding	29,743
Warrants Outstanding, Weighted-Average Remaining Contractual Term	6 years 109 days
Warrants Outstanding, Weighted-Average Exercise Price	$ 24.52
Warrants Exercisable	27,743
Warrants Exercisable, Weighted-Average Exercise Price	$ 24.72
Class of Warrants or Rights, Exercise Price Range, $30.01-$50.00 [Member]
NOTE 11 - STOCK OPTIONS AND WARRANTS (Details) - Schedule of Warrants Outstanding and Exercisable by Exercise Price Range [Line Items]
Warrants Outstanding	6,253
Warrants Outstanding, Weighted-Average Remaining Contractual Term	3 years 146 days
Warrants Outstanding, Weighted-Average Exercise Price	$ 48.36
Warrants Exercisable	4,253
Warrants Exercisable, Weighted-Average Exercise Price	$ 48.49
Class of Warrants or Rights, Exercise Price Range, $50.01-$60.00 [Member]
NOTE 11 - STOCK OPTIONS AND WARRANTS (Details) - Schedule of Warrants Outstanding and Exercisable by Exercise Price Range [Line Items]
Warrants Outstanding	543
Warrants Outstanding, Weighted-Average Remaining Contractual Term	2 years 73 days
Warrants Outstanding, Weighted-Average Exercise Price	$ 60
Warrants Exercisable	543
Warrants Exercisable, Weighted-Average Exercise Price	$ 60
Class of Warrants or Rights, Exercise Price Range, Greater than $60.00 [Member]
NOTE 11 - STOCK OPTIONS AND WARRANTS (Details) - Schedule of Warrants Outstanding and Exercisable by Exercise Price Range [Line Items]
Warrants Outstanding	8,092
Warrants Outstanding, Weighted-Average Remaining Contractual Term	4 years 146 days
Warrants Outstanding, Weighted-Average Exercise Price	$ 2,823.67
Warrants Exercisable	6,547
Warrants Exercisable, Weighted-Average Exercise Price	$ 1,675.28

NOTE 12 - COMMITMENTS AND CON47

NOTE 12 - COMMITMENTS AND CONTINGENCIES (Details) - USD ($)	Jun. 01, 2015	Mar. 19, 2015	Nov. 10, 2014	Sep. 30, 2015	Sep. 30, 2014
NOTE 12 - COMMITMENTS AND CONTINGENCIES (Details) [Line Items]
Stock Issued During Period, Shares, Settlement of Litigation (in Shares)		6,650		6,650
Loss Contingency, Damages Sought, Value			$ 2,300,000
Gain (Loss) Related to Litigation Settlement				$ (59,850)	$ 0
Note Payable, Settlement of Subordinated Debt, Accrued Interest and Guarantor Fees [Member] | Notes Payable, Other Payables [Member]
NOTE 12 - COMMITMENTS AND CONTINGENCIES (Details) [Line Items]
Gain (Loss) Related to Litigation Settlement	$ 1,169,058
Debt Instrument, Face Amount	$ 1,697,762
Debt Instrument, Term	5 years
Debt Instrument, Interest Rate, Stated Percentage	0.00%

NOTE 13 - FAIR VALUE MEASUREM48

NOTE 13 - FAIR VALUE MEASUREMENT (Details)	9 Months Ended
	Sep. 30, 2015USD ($)
Fair Value Disclosures [Abstract]
Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value	$ 399,328
Percentage of Stock Price Decrease	(82.00%)

NOTE 13 - FAIR VALUE MEASUREM49

NOTE 13 - FAIR VALUE MEASUREMENT (Details) - Schedule of Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2014
Total (gains) losses
Balance	$ 399,328
Fair Value, Inputs, Level 3 [Member] | Warrant [Member] | Embedded Derivative Financial Instruments [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance	149,920	$ 146,855
Net gain for the period included in earnings relating to the liabilities held at September 30, 2015	126,169
Total (gains) losses
Initial fair value of derivative		0
Mark-to-market	(126,169)	3,065
Transfers out of Level 3		0
Balance	23,751	149,920
Fair Value, Inputs, Level 3 [Member] | Debt [Member] | Embedded Derivative Financial Instruments [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance	591,351	256,956
Net gain for the period included in earnings relating to the liabilities held at September 30, 2015	134,784
Total (gains) losses
Initial fair value of derivative	591,360	1,443,708
Mark-to-market	(134,784)	(429,018)
Transfers out of Level 3	(672,350)	(680,295)
Balance	$ 375,577	$ 591,351

NOTE 14 - SUBSEQUENT EVENTS (De

NOTE 14 - SUBSEQUENT EVENTS (Details) - USD ($)	Oct. 12, 2015	Oct. 07, 2015	Oct. 01, 2015	Nov. 04, 2015	Sep. 30, 2015
Subsequent Event [Member]
NOTE 14 - SUBSEQUENT EVENTS (Details) [Line Items]
Stockholders' Equity, Reverse Stock Split	1-for-1,000
Subsequent Event [Member] | Settlement of Services [Member]
NOTE 14 - SUBSEQUENT EVENTS (Details) [Line Items]
Stock Issued During Period, Shares, Issued for Services (in Shares)				14,848
Stock Issued During Period, Value, Issued for Services				$ 65,015
Convertible Debt [Member] | Subsequent Event [Member]
NOTE 14 - SUBSEQUENT EVENTS (Details) [Line Items]
Debt Conversion, Converted Instrument, Shares Issued (in Shares)				252,157
Convertible Debt [Member] | Subsequent Event [Member] | Principal [Member]
NOTE 14 - SUBSEQUENT EVENTS (Details) [Line Items]
Debt Conversion, Original Debt, Amount				$ 136,095
Convertible Debt [Member] | Subsequent Event [Member] | Interest [Member]
NOTE 14 - SUBSEQUENT EVENTS (Details) [Line Items]
Debt Conversion, Original Debt, Amount				$ 7,499
Northstar Debt [Member] | Subsequent Event [Member]
NOTE 14 - SUBSEQUENT EVENTS (Details) [Line Items]
Debt Conversion, Converted Instrument, Shares Issued (in Shares)				38,678
Northstar Debt [Member] | Subsequent Event [Member] | Principal [Member]
NOTE 14 - SUBSEQUENT EVENTS (Details) [Line Items]
Debt Conversion, Original Debt, Amount				$ 100,000
Northstar Debt [Member] | Subsequent Event [Member] | Interest [Member]
NOTE 14 - SUBSEQUENT EVENTS (Details) [Line Items]
Debt Conversion, Original Debt, Amount				$ 12,705
Related Party Debt [Member] | Subsequent Event [Member]
NOTE 14 - SUBSEQUENT EVENTS (Details) [Line Items]
Debt Conversion, Converted Instrument, Shares Issued (in Shares)				274,211
Debt Conversion, Original Debt, Amount				$ 471,000
Magna Equities Notes Payable [Member] | Convertible Debt [Member] | Subsequent Event [Member]
NOTE 14 - SUBSEQUENT EVENTS (Details) [Line Items]
Debt Instrument, Interest Rate, Stated Percentage			12.00%
Debt Instrument, Face Amount			$ 160,000
Debt Instrument, Maturity Date			Aug. 1, 2016
Debt Instrument, Convertible, Conversion Price (in Dollars per share)			$ 0.72
Debt Instrument, Convertible, Terms of Conversion Feature			or if a registration statement registering the underlying shares of common stock is not filed within 70 days, 45% of the lowest trading price during five consecutive trading days prior to conversion with anti-dilutive provisions
Fourth Man, LLC Notes Payable [Member] | Convertible Debt [Member]
NOTE 14 - SUBSEQUENT EVENTS (Details) [Line Items]
Debt Instrument, Face Amount					$ 100,000
Debt Instrument, Maturity Date					Jul. 31, 2016
Debt Instrument, Convertible, Terms of Conversion Feature					convertible into shares of common stock, at Fourth Man’s option, at a 47% discount to the lowest closing bid price of the common stock during the 10 trading day period prior to conversion
Fourth Man, LLC Notes Payable [Member] | Convertible Debt [Member] | Subsequent Event [Member]
NOTE 14 - SUBSEQUENT EVENTS (Details) [Line Items]
Debt Instrument, Interest Rate, Stated Percentage		9.50%
Debt Instrument, Face Amount		$ 25,000
Debt Instrument, Maturity Date		Oct. 6, 2016
Debt Instrument, Convertible, Terms of Conversion Feature		The Note is convertible into common stock, at Fourth Man’s option, at a 47% discount to the lowest daily closing trading price of the common stock during the 10 trading day period prior to conversion.
Debt Instrument, Debt Default, Description of Violation or Event of Default		In the event the Company prepays the Note in full, the Company is required to pay off all principal at 150%, interest and any other amounts.